



Universiteit
Leiden
The Netherlands

Pathogenesis and treatment of skeletal metastasis : studies in animal models

Buijs, J.T.

Citation

Buijs, J. T. (2009, January 21). *Pathogenesis and treatment of skeletal metastasis : studies in animal models*. Retrieved from <https://hdl.handle.net/1887/13413>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/13413>

Note: To cite this publication please use the final published version (if applicable).

Chapter 1

General Introduction

Partly published in
Cancer Letters 2008, *in press*

Jeroen T Buijs¹
Gabri van der Pluijm^{1,2}

Departments of Urology¹ and Endocrinology²,
Leiden University Medical Center,
Leiden, The Netherlands



General introduction

Table of Contents	11
1 Clinical Problem of Skeletal Metastasis	13
2 Paget's 'Seed and Soil' Hypothesis	15
3 'The Seed': Tumor Progression and Metastasis	15
3.1 Carcinogenesis	15
3.2 Angiogenesis	17
3.3 Acquisition of an Invasive Phenotype: Epithelial-to-Mesenchymal Transition	19
3.4 Intravasation, Circulation and Extravasation	22
3.4.1 Vertebral Venous System	23
4 'The Soil': Bone/Bone Marrow Microenvironment	23
4.1 Bone	24
4.1.1 Bone Cells	24
4.1.2 Bone Matrix	26
4.1.3 Bone Turnover	26
4.2 Bone Marrow	26
4.3 TGF- β Superfamily	29
4.4.1 Signaling Pathways	29
4.4.2 Regulation of Activity	33
4.4.3 Physiologic and Pathophysiologic Functions	36
5 'Seed-Soil' Interactions	37
5.1 Bone Turnover and Skeletal Metastasis	39
5.2 Bone Metastatic Phenotype	40
5.2.1 Osteolytic Bone Metastasis	40
5.2.2 Osteosclerotic Bone Metastasis	42
6 Animal Models of Bone Metastasis	44
6.1 Spontaneous Mammary and Prostate Cancer in Animals	44
6.2 Transgenic Induction of Mammary and Prostate Cancer in Mice	45
6.3 Syngeneic and Xenograft Models of Bone Metastasis	45
6.3.1 Routes of Cancer Cell Inoculation	45

6.4	Subcutaneous Transplantation of Human Bone	47
6.5	<i>In Vivo</i> Imaging	47
7	Treatment of Bone Metastases	47
7.1	Treatment Strategies	48
7.1.1	Bone Resorption Inhibitors	48
7.2	Future Perspectives	50
8	Aim and Outline of Thesis	50
9	References	51

1 Clinical Problem of Skeletal Metastasis

Cancers account for over 20% of deaths in Western countries and these are primarily due to the spread of cancer to distant organs ¹. It has long been recognized that primary cancers spread to distant organs with characteristic preference ², and the skeleton is one of the most common organs to be affected by metastatic cancer ³⁻⁶. Breast and prostate cancer are osteotropic tumors, i.e., carcinomas that have a special predilection to form bone metastases. At postmortem examination ~70% of patients dying of these cancers have evidence of metastatic bone disease (Table 1) ^{5,7}. Carcinomas of thyroid, kidney and bronchus also commonly give rise to bone metastases, with an incidence of 30% to 40%, but tumors of the gastrointestinal tract rarely (<10%) produce bone metastases. In these routine autopsies, the true incidence of metastases in the skeleton is most likely underestimated, and more accurate assessments may be determined by scintigrams. Together, breast and prostate cancer probably account for more than 80% of cases of metastatic bone disease ⁶.

Table 1 Incidence of skeletal metastases at autopsy
Based on all autopsy studies listed by Galasko ⁵ + study from Walther ⁷

Primary tumor site	Number of studies	Incidence (%) of bone metastases	
		Median	Range
Breast	13	67	47– 85
Prostate	8	66	33 – 85
Thyroid	5	38	28 – 60
Lung	6	36	30 – 55
Kidney	4	34	33 – 40
Esophagus	3	6	5 – 7
Gastro-intestinal tract	5	7	3 – 11
Rectum	3	11	8 – 13
Uterine/ cervix	1	50	x
Ovaries	1	9	x
Liver	1	16	x

Breast and prostate cancer are the most commonly diagnosed malignancies ¹ and the second leading cause of cancer death in the western world in women and men, respectively ¹. At time of diagnosis, most patients with breast ³ and prostate ⁸ cancer do not have clinicopathologic signs of overt distant metastases. Thus, after resection of the primary tumor and all positive lymph nodes, these patients are in complete clinical remission. However, disseminated tumor cells (DTCs) can already be present in bone marrow (BM) ⁹⁻¹³, a clinical situation called *minimal residual disease (MRD)*. The DTCs that are still present in BM are frequently resistant to current treatment (chemo-/hormone therapy), and can stay

dormant for many years^{10,14,15}. So, only the very small subfraction of the DTCs that have acquired the abilities of metastasizing to, surviving in, and colonizing the bone/BM microenvironment, can eventually result in the development of an overt bone metastasis. Only this subpopulation of DTCs can, therefore, be regarded as true *metastasis-initiating cells* (MICs). Even though, the general presence of DTCs in BM at time of diagnosis is significantly associated with the formation of distant metastases, particularly to bone^{9,10}.

The clinical courses of patients with breast and prostate cancer with a first recurrence in bone are relatively long, with a median survival of 24 and 40 months⁴. This is in marked contrast to those with first recurrence of breast cancer in the liver (3 months)³. Moreover, patients with disease that remains confined to the skeleton have a better prognosis than those with subsequent visceral involvement¹⁶. In these patients, the decline in quality of life and eventual death is due almost entirely to skeletal complications and their subsequent treatment^{17,18}. The prognostic indicators that metastatic breast cancer remains confined to skeleton are low histological grade (well-differentiated), lobular subtype (vs. ductal), postmenopausal state and a low number of positive lymph nodes at time of surgery. For patients with breast cancer, good prognostic factors for survival after the development of bone metastases are low histological grade (well-differentiated), positive estrogen receptor status, a long disease free interval, and increasing age¹⁶.

Bone pain is the most common complication of metastatic bone disease, resulting from structural damage, periosteal irritation, and nerve entrapment¹⁹. In addition, hypercalcaemia occurs in 5–10% of all patients with advanced cancer but is most common in patients with breast cancer, multiple myeloma, and squamous carcinomas of the lung^{20,21}. Pathologic fractures are a relatively late complication of bone involvement.

Bone metastases in prostate cancer patients are predominantly osteoblastic (osteosclerotic), characterized by increased bone formation due to exaggerated osteoblastic activity. In contrast, patients with breast, lung, and kidney cancers have predominantly osteolytic bone metastases, characterized by increased bone degradation resulting from enhanced osteoclastic activity^{18,21,22}. However, patients can have both osteolytic and osteoblastic bone metastases, or mixed lesions containing both elements (see paragraph 5.2, 'Bone Metastatic Phenotype').

In this chapter, a brief introduction into the multistep process of metastasis will be given. Subsequently, this chapter will give an overview of our current understanding of the molecular and biological mechanisms involved in the process of bone metastasis formation, including a summary of normal bone physiology and therapeutic opportunities. Finally, the outline of this thesis will be presented. But first, to set the scene, the next paragraph will describe the well-established 'seed and soil' hypothesis as postulated by Stephen Paget in 1889.

2 Paget's 'Seed and Soil' Hypothesis

Over a century ago Stephen Paget was the one of the first who observed a non-random pattern of metastasis to certain organs by analyzing autopsy records of 735 women who had died of breast cancer². He proposed the 'seed and soil' hypothesis in which he compared the seeding of cancer cells to the dispersal of the seeds of plants. Accordingly, circulating cancer cells ('seeds') disperse in all directions, but can accomplish metastases only in the organs where the microenvironment ('soil') is permissive for their growth, i.e., osteotropic cancer cells possess certain properties that enable them to grow in bone, and the bone/bone marrow microenvironment provides a fertile soil on which to grow. Ever since, the hypothesis holds forth. Based on this hypothesis, the 'seed' (see paragraph 'The Seed: Tumor Progression and Metastasis'), the 'soil' ('The Soil: Bone/Bone Marrow') and their interactions ('Seed-Soil Interactions') will be specifically addressed in this chapter.

3 'The Seed': Tumor Progression and Metastasis

Since Paget postulated the 'seed and soil' hypothesis, our understanding of the metastatic process has increased tremendously. It has now been well-established that tumor progression and metastasis is a multistep process characterized sequentially by carcinogenesis and growth of the primary tumor, angiogenesis, cell invasion, access to the systemic blood circulation (intravasation), survival in circulation, arrest in microvasculature and subsequent extravasation, and growth at distant organs, (reviewed in²³) (Fig. 1). These processes will be discussed in more detail in the next paragraphs.

3.1 Carcinogenesis

The great majority of cancers (>80%) occur in epithelial tissues, yielding carcinomas^{1,24}. Epithelial tissues are generally built according to a common set of architectural principles; relatively thin sheets of epithelial cells are separated from complex layers of stroma by a basement membrane. By definition, carcinomas begin on the epithelial side of the basement membrane as hyperplastic and dysplastic growth progressing to a carcinoma *in situ*, and are considered to be *benign*. Nevertheless, carcinoma *in situ* may develop into an invasive malignancy as it breaks through the basement membrane and, by then, is classified as *malignant*, and commonly called a cancer²⁴.

In the normal, healthy situation tissue fibroblasts regulate the proliferation and differentiation of epithelial tissues²⁵. Likewise, tumor-stroma interactions also play a critical role in development and progression of carcinomas^{26,27}. For example, transformed stroma can induce malignancy in lung²⁸ and mammary epithelia²⁹, and conversely, normal fibroblasts have been reported to convert malignant epithelia to morphologically benign lesions

³⁰. Cancer-associated fibroblasts (CAFs) could also induce tumorigenesis in non-malignant prostatic epithelial cells, mediated via CAF-secreted stromal-derived factor (SDF-1) and transforming growth factor- β (TGF- β) ³¹. This is in line with the dual role that is implicated for TGF- β in carcinogenesis. In normal and non-malignant epithelial cells TGF- β acts as a potent growth inhibitor ^{32,33}. However, different types of carcinomas (e.g., Ras-transformed cells) can become refractory to growth inhibition. In fact, TGF- β can potentiate tumorigenesis and contribute to invasiveness by stimulating an epithelial-to-mesenchymal transition (EMT) ³⁴⁻³⁸ (see paragraph 3.3 'Acquisition of an Invasive Phenotype: Epithelial-to-Mesenchymal Transition')




Figure 1 Main steps in tumor progression and metastasis. Cellular transformation due to genomic instability and changes can result in dysplasia, which may eventually result in a carcinoma *in situ*. At the same time, new blood vessels are formed (angiogenesis). This will facilitate cancer cells to enter into the systemic circulation (intravasation), after they have undergone an epithelial-to-mesenchymal transition (EMT). The EMT confers an invasive phenotype to the cancer cells, including loss of cell-cell adhesion, increased motility and matrix degradation. Aggregates of cancer cells with platelets and leukocytes may form cell emboli that may consequently be protected from the immune reaction. Arrest in the capillaries may be facilitated by mechanical mechanism and by adhesion to endothelium-specific cell adhesion molecules. Eventually some of the micrometastases may acquire the ability to colonize the tissue in which they have landed, enabling them to form a macrometastasis. The small probability of successfully completing all steps of this cascade explains the low likelihood that any single cancer cell leaving a primary tumor will succeed in becoming the founder of a distant, macroscopic metastasis.

Many other tumor–stroma interactions are also mediated by members of the TGF- β superfamily³⁹, e.g., the involvement of TGF- β signaling in fibroblasts was determined by conditional inactivation of the TGF- β type II receptor (TBRII) gene in mouse fibroblasts (TBRII^{fspK0})⁴⁰. The loss of TGF- β responsiveness in fibroblasts resulted in intra-epithelial neoplasia in prostate and invasive squamous cell carcinoma of the forestomach, both associated with an increased abundance of stromal cells. TGF- β and other members of the TGF- β superfamily will be discussed in greater detail in the section ‘TGF- β superfamily members’.

For over 150 years, it has been anticipated that only a minority of cells within a tumor are responsible for tumor growth and development (reviewed in⁴¹). Over the past few years it has become possible to isolate and characterize these tumor-initiating cells, first from hematological malignancies^{42,43} and recently also from many solid tumors, including breast⁴⁴ and prostate cancer^{45,46}. Cell fractions of as few as 100 to 200 sorted cells with a particular phenotype from human primary breast⁴⁴ and prostate cancer⁴⁶ could successfully be orthotopically transplanted in immune-deficient mice, whereas much larger numbers (10^4 – 10^5) of the rest of the cells depleted of that particular phenotype could not. Many of these isolated tumor-initiating cells share (surface) markers with somatic stem cells and both share the characteristics of 1) self-renewal, 2) an indefinite proliferative potential, 3) differentiation along one or several diverse lineages, and 4) homing to allow cells to migrate and seek their niche. For these reasons, tumor-initiating cells have been given the popular name ‘cancer stem cells (CSCs)’^{47,48}. The concept of CSCs underscores the importance of targeting the correct cells for cancer therapy. Eliminating only the more differentiated, rapidly dividing cells by chemo- or radiotherapy is not likely to result in successful long term remission if the less differentiated and slower proliferating CSCs remain to repopulate the tumor. At present, much remains to be learned about the identification, molecular signature and functional plasticity of the CSCs⁴⁹.

3.2 Angiogenesis

Angiogenesis, also referred to as neovascularization, is the process of new capillary formation from pre-existing vessels^{50,51}. Angiogenesis is a complex multistep process that involves dissolution of the basement membrane of the vessel, extracellular matrix degradation, migration and proliferation of endothelial cells, capillary differentiation, stabilization and anastomosis. These processes are tightly regulated by inducers and inhibitors of endothelial proliferation, migration and differentiation⁵².

In malignancy, tumor cells can switch from an angiogenesis-inhibiting phenotype to an angiogenesis-stimulating phenotype, the so-called ‘*angiogenic switch*’⁵³. This angiogenic switch is essential for tumor growth beyond 1–2 mm³ without neovascularization⁵⁴. In breast cancer, tumor-induced angiogenesis is already evident at the pre-invasive stage of ductal carcinoma *in situ*, characterized by a rim of microvessels formed around the ducts that are filled with proliferative epithelial cells. So before carcinoma cells breach the base-

ment membrane, they often succeed in stimulating angiogenesis on the stromal side of the membrane, by dispatching angiogenic factors through this porous barrier to endothelial cells within the stroma⁵⁵. Angiogenesis is not only required to meet the growing metabolic demands of the tumor by supplying nutrients and oxygen, but also provides routes for tumor dissemination and metastasis^{54,56}. Not surprisingly, high blood vessel counts or production of factors that stimulate angiogenesis are independent predictors of poor prognosis in many primary solid cancers⁵⁷⁻⁶¹. A variety of factors, including hypoxia and genetic changes in the tumor cells, contribute to the increase in production of angiogenic factors. Furthermore, cells within the activated tumor stroma also play an important role in increasing the production of vascular endothelial growth factors (VEGFs) and other angiogenic factors, including basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF)^{26,62}.

VEGF-A is a specific endothelial cell mitogen and regarded as the most important inducer of angiogenesis. It is constitutively expressed in many cancers^{62,63}. Its importance was underlined when it was demonstrated that monoclonal antibodies against VEGF-A inhibited the growth of various tumors in animal models⁶⁴. Angiogenesis is not only essential for the primary tumor to grow and metastasize, but is required for the outgrowth of a micrometastasis into an overt (bone) metastasis as well^{65,66}.

Besides weakly stimulating angiogenesis, VEGF-C and VEGF-D are the main inducers of tumor lymphangiogenesis, and are overexpressed in breast and prostate cancers as well⁶⁷. Accordingly, VEGF-C and VEGF-D expression levels have been correlated with increased number of lymph vessels in cancer patients, and have been shown to promote metastatic spread via the lymphatics^{68,69}.

In addition to (lymph)angiogenesis, evidence is accumulating that malignant tumors are often capable of inducing other structures that may contribute to (invasive) growth and dissemination (reviewed in⁷⁰). Networks that stain positive with periodic acid-Schiff (PAS) have been observed in different types of cancers^{62,71-73}. In both uveal and cutaneous melanoma, these structures have been shown to be of prognostic significance⁷³⁻⁷⁵.

The PAS reaction is a non-specific indicator for polysaccharides, which are present in basement membranes, including those of blood vessels. The PAS-positive patterns may represent (a mixture of): blood vessels/vascular network^{72,74}, fibrovascular tissue^{76,77}, tumor cells⁷⁸, or a fluid conducting meshwork⁷¹. Maniotis and co-workers have shown that highly aggressive, but not non-aggressive, melanoma cells are capable of forming highly patterned vascular channels *in vitro* that are composed of a PAS-positive basement membrane in the absence of endothelial cells and fibroblasts⁷⁸. These channels formed *in vitro* are morphologically identical to PAS-positive channels in histological preparations of highly aggressive primary and metastatic uveal and cutaneous melanomas. The generation of microvascular channels by aggressive tumor cells was termed "vasculogenic mimicry" (VM) to emphasize their *de novo* generation without participation by endothelial cells⁷⁸⁻⁸⁰. Since then, VM has

been identified in several cancers, including prostate⁸¹ and inflammatory breast cancer⁸². However, the and co-workers remains a debatable subject, and Although some investigators state that the original findings of VM by Maniotis are not convincing^{83,84}, or lack novelty⁸⁵, VM is becoming increasingly accepted as a concept for tumor cell plasticity

3.3 Acquisition of an Invasive Phenotype: Epithelial-to-Mesenchymal Transition

In the pre-invasive stage of carcinoma *in situ*, with or without increased neovascularization in the underlying stroma, the first step leading to dissemination is the acquisition of local invasiveness²³. The organization of the epithelial cell layers in normal tissue is incompatible with the motility and invasiveness displayed by malignant cancer cells. Therefore, in order to acquire motility and invasiveness, cancer cells must shed many of their epithelial characteristics, detach from epithelial sheets, and undergo a drastic alteration, which is referred to as the epithelial-to-mesenchymal transition (EMT)^{37,86}.

In order to invade adjacent cell layers carcinoma cells are required to remodel the nearby tissue environment by excavating passageways through the extracellular matrix (ECM) and pushing aside any cells that stand in their path⁸⁷. The most important effectors to create space in the ECM are matrix metalloproteinases (MMPs)(reviewed in⁸⁸). In carcinomas, the great bulk of these proteases are secreted by recruited stromal cells, notably macrophages, mast cells and fibroblasts, rather than neoplastic cells^{26,89}. During the course of degrading ECM components (e.g., fibronectin, tenascin, laminin, collagens, and proteoglycans), MMPs can also activate certain growth factors that have been tethered in inactive form to the ECM or to cell-surfaces⁸⁸.

The EMT displayed by cancer cells is reminiscent of the highly conserved and fundamental process of EMT that occurs during early embryonic development⁹⁰⁻⁹³. During gastrulation, embryonic epithelial cells need to undergo an EMT in order to migrate to a new environment. Eventually these embryonic cells may regain a fully differentiated epithelial phenotype via a mesenchymal-to-epithelial transition (MET) (Fig. 2)⁹⁴⁻⁹⁸. The transition to a more mesenchymal, motile cellular phenotype is the result of a complex physiological process that includes dissolution of adherens junctions, loss of cell polarity, a change to spindle-like cell morphology, cytoskeletal reorganization, increased cell motility, loss of epithelial markers and induction of mesenchymal markers^{90-93,99}. Increased vimentin expression and perturbation of E-cadherin-mediated cell adhesion appear as hallmarks of this process^{37,100-102}. Accordingly, it has been shown that once E-cadherin expression is suppressed, other cell-physiologic changes associated with the EMT seem to follow suit. Additionally, re-expression of E-cadherin in different types of cancer strongly suppressed the invasiveness and metastatic dissemination^{103,104}.




Figure 2 The cycle of epithelial-cell plasticity as observed in embryonic development during gastrulation. The diagram shows the cycle of events during which epithelial cells are transformed into mesenchymal cells and vice versa. The different stages during EMT (epithelial-to-mesenchymal transition) and the reverse process MET (mesenchymal-to-epithelial transition) are regulated by effectors of EMT and MET, which influence each other. Important events during the progression of EMT and MET, including the regulation of the tight junctions and the adherens junctions, are indicated. ECM, extracellular matrix; ZO-1, zona occludens 1; SMA, smooth muscle actin; FSP-1, fibroblast-specific protein-1; adapted from ⁹⁷.

Under non-pathological conditions, EMT and MET are both non cell-autonomous processes, and thus require an external stimulus to be initiated ^{92,93,105}. In malignancy, both genetic alterations and tumor environment may be able to induce EMT in tumor cells. Transformed mammary epithelial cells that are in direct contact with the surrounding stromal cells can undergo an EMT, indicated by expression of vimentin and an elongated, fibroblastic shape ¹⁰⁵. However, established metastases of most cancers recapitulate the differentiated phenotype of their primary tumors including re-expression of E-cadherin ^{106,107}. Therefore, the important steps that enable metastasis can be reversible, and are not explained solely by irreversible genetic alterations, indicating the existence of a dynamic component to human tumor progression ^{108,109}.

TGF- β is one of the main inducers of EMT as was demonstrated in Ras-transformed mammary and other epithelial cells¹¹⁰⁻¹¹² (Fig. 3). These mammary epithelial cells were even able to maintain the mesenchymal, fibroblast-like state through autocrine TGF- β signaling^{110,111}. However, when TGF- β was removed (by adding fresh medium or neutralizing antibodies) they reverted back to their epithelial appearance¹¹⁰, indicating that they had undergone an MET. Another example of a self-sustaining positive feedback loop for EMT is the expression of $\alpha v\beta 6$ integrin by tumor cells, which can activate the latent form of TGF- β produced by the stroma cells¹¹³.




Figure 3 Overview of the molecular networks that regulate EMT. A small selection of EMT regulators, and a limited representation of their crosstalks are illustrated. TGF- β is one of the main inducers of EMT. However, several normal and transformed epithelial cell lines need co-activation of Ras-signaling, to overcome transforming growth factor- β (TGF- β)-induced apoptosis. It is likely that the EMT is normally triggered in response to a mixture of signals that carcinoma cells receive from the stroma together with intracellular signals, e.g. the signal released by the Ras oncogene. FGF, fibroblast growth factor; HGF, hepatocyte growth factor; EGF, epidermal growth factor; RTK, receptor tyrosine kinase; FAK, focal adhesion kinase; GSK3 β , glycogen-synthase kinase-3 β ; MAPK, mitogen-activated protein kinase; NF- κ B, nuclear factor- κ B; TAK1, TGF- β -activated kinase-1.

Additional microenvironmental signals that can induce EMT are ECM components and soluble factors, including other members of the TGF- β superfamily, fibroblast growth factor (FGF) family, epidermal growth factor (EGF), hepatocyte growth factor (HGF, alias scatter factor) ¹¹⁴, insulin-like growth factor (IGF)-II ¹¹⁵ and proteins of the wntless (Wnt) and Hedgehog (Hh) families (Fig. 3) (reviewed in ^{86,97}). It is important to take into account that besides the tumor–stroma interactions at the edge of tumor, infiltrating cells (e.g., lymphocytes, macrophages) might also be able to induce EMT in tumor cells. Moreover, accumulation of irreversible mutations could also trigger invasive behavior, particularly resulting in poorly differentiated anaplastic cancers, in which no re-differentiation is detectable in primary cancers and metastases ^{116,117}.

Both the EMT concept and the CSC concept cover distinct aspects of tumor progression and metastasis, but can be converged into a single concept, which subdivides CSCs in the *stationary cancer stem cell* (SCS cell) and the *migrating cancer stem cell* (MCS cell) ¹⁰⁹. SCS cells, which are still embedded in the epithelial tissue, are already active in benign precursor lesions, such as carcinoma *in situ*, and persist in differentiated areas throughout all steps of tumor progression; however SCS cells cannot disseminate. MCS cells, which are located predominantly at the tumor–stroma interface, are derived from SCS cells through the acquisition of a (transient) EMT in addition to stemness. This concept takes into account two important requirements — CSCs that have undergone EMT can disseminate, and DTCs that retain stem-cell functionality can form metastatic colonies. So, the MCS cell concept combines the important current tumor initiation and progression concepts — the cancer stem cell and EMT concept — and it integrates both genetic alterations and the tumor environment as combined driving forces of malignant progression. However, the concept still awaits verification in different models of tumor progression for various types of cancer.

3.4 Intravasation, Circulation and Extravasation

Once tumor cells detach from the primary tumor via EMT, they can intravasate into the blood or lymphatic system. Via the lymphatic system, tumor cells can form lymph node metastases in close proximity of the primary tumor, or eventually enter the blood circulation in the left and right subclavian veins. Tumor cells that directly, or indirectly, enter the blood vessels can spread via the pulmonary circulation throughout the whole body, where they may found new colonies. However, the event of a successful development of a distant metastasis is very rare, and most cancer cells are not able to by-pass the capillary bed of the lungs. This is substantiated by the fact that in animal models, it has been estimated that 3–4 10^6 cancer cells/g of tumor can reach the bloodstream per day ¹¹⁸, but that only a very small minority of cancer cells reaching the blood will survive and grow at the distant sites.

In the blood circulation, cancer cells may interact with platelets ^{119,120} and leucocytes, to create aggregates or emboli. These may increase resistance to shear stress and protect from immune-cell-mediated tumor cell clearance ^{23,121}. These aggregates may also

facilitate mechanical trapping in the capillaries of different organs, and promote extravasation¹²². Once the tumor cells have exited the circulation, the activated platelets are a source of factors that are able to induce angiogenesis¹²³, stimulate tumor cell proliferation, and indirectly enhance osteoclastic activity in the bone environment^{119,120}.

3.4.1 Vertebral Venous System

As first demonstrated by Batson, there exists a *vertebral venous system*, which is composed of three freely communicating thin-walled valveless networks: intraosseous vertebral veins, epidural and paravertebral venous complexus^{124,125}. The pressure in the intraosseous veins is always 35–50% higher than on the caval side of the venous circulatory system, enabling blood to flow along this pressure gradient from the vertebrae to the inferior vena cava. However, the absence of valves makes it possible that an increase of abdominal pressure, such as caused by coughing, lifting or palpation, could cause retrograde flow. Moreover, Batson showed in human cadaver and animal experiments that venous blood from both the pelvis and the breast flowed not only into the vena cava, but also directly into the vertebral venous system^{124,125}. This system, in which blood is thus continuously subjected to arrest and reversal of the direction of the flow, could enable cancer cells from the pelvic region and breast to by-pass the pulmonary circulation, providing an explanation for the predilection of breast and prostate cancer to produce metastases in the axial skeleton. This hypothesis was tested by Coman and De Long, who performed an inoculation with cancer cells in the femoral veins during a moderate temporarily increase in intra-abdominal pressure in experimental animals. Indeed, an increased abdominal pressure enabled cancer cells to directly enter, and form metastases within the vertebral venous system^{124,126}.

Although the system of blood flow in the *vertebral venous system* can, at least in part, explain the high incidence of bone metastases in the vertebrae, it cannot explain that human cancers, particularly breast and prostate cancer, metastasize with high frequency to other bones⁵. For this explanation, we may need to have a closer look at the interactions between the 'seed' and the 'soil'. But before these interactions will be discussed, the next paragraph will first comprehensively describe the properties of the soil.

4 'The Soil': Bone/Bone Marrow Microenvironment

In addition to anatomy, the pathophysiology of bone metastasis is determined by multiple direct and indirect interactions between metastatic cancer cells and the bone/BM microenvironment (including BM cells, bone cells, and bone matrix). First, the normal physiology of the bone/BM microenvironment will first be delineated below.

4.1 Bone

Bone is a highly mineralized tissue that provides mechanical support and metabolic functions to the skeleton. It can be formed by either intramembraneous ossification or endochondral ossification. Intramembraneous ossification occurs when mesenchymal precursor cells differentiate directly into bone-forming osteoblasts, a process employed in generating the flat bones of the skull as well as in adding new bone to the outer surfaces of long bones. In contrast, endochondral bone formation entails the conversion of an initial cartilage template into bone and is responsible for generating most bones of the skeleton (reviewed in ¹²⁷).

4.1.1 Bone Cells

The formation and degradation of bone matrix is regulated by normal bone cells, namely the osteoblast and osteoclast, respectively. In normal bone, there is a balanced remodeling sequence: first, osteoclasts resorb bone matrix, and then osteoblasts form bone matrix at the same site (reviewed in ¹²⁷).

4.1.1.1 Osteoclasts

Osteoclasts are specialized cells derived from the monocyte-macrophage hematopoietic lineage that adhere to and, once activated, degrade bone matrix (reviewed in ^{128,129}). Activated osteoclasts resorb bone by secreting the protease cathepsin K that dissolves the matrix, and produce acid that releases bone mineral into the extracellular space under the ruffled border of the plasma membrane of osteoclasts, which faces bone (reviewed in ¹²⁹). The adherence of osteoclasts to the bone surface is critical for the bone resorptive process, since agents that interfere with osteoclast attachment block bone resorption ¹³⁰. Although osteoclasts can be influenced by various locally produced cytokines as well as systemic hormones, two specific hematopoietic factors — macrophage colony stimulating factor (M-CSF, alias CSF1) and receptor activator of nuclear factor κ B ligand (RANKL) — are both necessary and sufficient for the formation and activation of osteoclasts. M-CSF is produced by stromal cells and osteoblasts and interacts with its receptor c-fms expressed on macrophage precursors to stimulate proliferation. Accordingly, *op/op* mice that lack expression of M-CSF due to a gene mutation are deficient in osteoclasts (and macrophages), resulting in enhanced bone formation ¹³¹⁻¹³³. Substitution of M-CSF reversed the osteopetrotic phenotype in *op/op* mice ¹³⁴. While M-CSF is crucially important in the early steps of osteoclastogenesis, RANKL — expressed on osteoblasts and stromal cells — is critically involved in maturation and activation of the osteoclasts. Interaction of RANKL with the membrane receptor RANK on osteoclast precursors induce — by signaling through the nuclear factor- κ B (NF- κ B) and Jun N-terminal kinase (JNK) pathways — commitment of the monocyte-macrophage precursor to the osteoclast lineage ¹³⁵⁻¹³⁹. The importance of RANK-RANKL binding in the formation of osteoclasts has been demonstrated clearly by *RANKL* ^{140,141} and *RANK* ¹⁴² knock-out mice. Both knock-out mice lack osteoclasts, and

as a result, severe osteopetrosis develops. In addition, the development of B cells and T cells is defective in these animals. Likewise, mice bearing mutations or deletions in intracellular signal molecules critically involved in RANK signaling, such as c-Fos¹⁴³, c-Jun¹⁴⁴ and NFATc¹⁴⁵, also develop osteopetrosis. Various locally produced cytokines as well as systemic calcitropic hormones — including parathyroid hormone (PTH), 1,25-dihydroxyvitamin D3, and prostaglandins — indirectly stimulate osteoclastogenesis by upregulation of RANKL expression on marrow stromal cells and osteoblasts^{139,146,147}. In addition, many cytokines, such as interleukin (IL)-1 and tumor necrosis factor- α , are also able to directly affect osteoclasts¹²⁸.

Osteoprotegerin (OPG) was identified as the decoy receptor for RANKL, and is normally present in the BM^{139,148}. OPG is a member of the superfamily of tumor necrosis factor receptors and inhibits the differentiation and resorption of osteoclasts *in vitro* and *in vivo*^{136,148,149}. The ratio of RANKL to OPG regulates the formation and activity of osteoclasts¹⁵⁰. Accordingly, OPG-deficient mice display marked osteoporosis^{151,152}, whereas overproduction of OPG in these mice causes severe osteopetrosis¹⁵³.

4.1.1.2 Osteoblasts and Osteocytes

Osteoblasts are the bone-forming cells, responsible for the production of the matrix constituents. They are always found lining the layer of bone matrix that they are producing before it is calcified, referred to as osteoid tissue. Osteoid tissue exists because of a time lag between matrix formation and its subsequent calcification (the osteoid maturation period), which is approximately 10 days^{127,154}. Osteoblasts never appear to function individually, and are always found in clusters of cuboidal cells along the bone surface (~100 to 400 cells per bone-forming site). Osteoblasts arise from local mesenchymal stem cells (MSCs), which are precursor cells for many cell types involved in bone formation, such as osteoblasts, osteocytes and chondrocytes, and for other mesenchymal cell lineages, such as fibroblasts, myoblasts, adipocytes, and neuronal cells¹⁵⁵. For differentiation towards an osteoblast, MSCs first undergo proliferation, become committed and then differentiate into a pre-osteoblast — producing alkaline phosphatase — and subsequently into a mature osteoblast, producing increasing amounts of osteocalcin and calcified matrix¹⁵⁶. Runt-related transcription factor 2 (Runx2; alias core-binding factor α 1) and Osterix are crucial transcription factors that drive the expression of most genes associated with osteoblast differentiation^{157,158}. Accordingly, bone does not develop in mice that lack the *Runx2* gene^{159,160}. The commitment of MSCs to the osteoblast lineage is regulated by at least three major morphogenetic pathways, the BMP^{161,162}, the Hh¹⁶³, and the Wnt¹⁶⁴ signaling pathway. These pathways can still be influenced and fine-tuned by factors, such as PTH, PTH-related protein (PTHrP), platelet-derived growth factor (PDGF), fibroblast growth factors (FGFs), TGF- β , sex steroids and other hormones (reviewed in¹⁵⁴). When osteoblasts become embedded in the bone matrix, they differentiate into *osteocytes*, the most abundant cells in

mature bone. Because they can function as mechanosensors, osteocytes are considered to modulate bone remodeling in response to bone loading (reviewed in ^{127,165}).

4.1.2 Bone Matrix

Bone is composed of an organic matrix that is strengthened by deposits of calcium salts. Type I collagen constitutes approximately 90-95% of the organic bone matrix, whereas noncollagenous proteins comprise the remaining 5-10%. Crystalline salts deposited in the matrix are primarily calcium and phosphate in the form of hydroxyapatite ¹²⁷. Noncollagenous proteins can be subdivided in 1) cell attachment proteins, 2) proteoglycans, 3) γ -carboxylated (gla) proteins, and 4) growth factors (e.g., IGFs, TGF- β s, FGFs, PDGFs, and BMPs) (reviewed in ¹⁶⁶). Any of the attachment proteins, e.g., osteopontin (OPN), bone sialoprotein (BSP), and vitronectin and collagen type I facilitate interactions with integrins that are expressed by specialized bone and HSC cells as well as osteotropic cancer cells ^{167,168}. The mineralized bone also stores a variety growth factors, including IGFs, TGF- β s, FGFs, PDGFs, and BMPs. Since bone continuously remodels, bone-stored growth factors, such as IGFs, TGF- β s, FGFs, PDGFs, and BMPs ^{169,170}, are constantly released in the BM cavity by osteoclastic bone resorption, affecting growth of bone metastatic cells as will be discussed in detail in paragraph 5: 'Seed-Soil Interactions'. IGF-I is the growth factor that is stored most abundantly in the bone matrix, and upon release, it can play an important role in stimulation of (cancer) cell proliferation and chemotaxis, and inhibition of apoptosis ¹⁷¹. TGF- β s and BMPs will be discussed in detail in paragraph 4.4.

4.1.3 Bone Turnover

Adult bone is continuously remodeled by bone resorption and subsequent bone formation in temporary anatomic structures, called the basic multicellular units (BMUs), described by Frost more than forty-years ago ¹⁷² (Fig. 4). These two phases are in a balanced sequence and the net result is replacement of old bone with new bone, thus maintaining structural integrity of the skeleton throughout adult life ¹⁷²⁻¹⁷⁴. The actual number and activity of these BMUs determine the bone turnover rate (or status) and they are under the control of mechanical stress, cytokines and hormones. Upon resorption, local mitogenic factors, such as TGF- β , that are embedded within the calcified matrix are released and activated ¹⁷⁵. These local factors, along with the systemic factors PTH, estrogen, and prostaglandin, recruit new osteoblasts at the BMU to fill the gap created by osteoclasts.

4.2 Bone Marrow

Bones are not entirely compact, and the center of the bone generally consists of spongy bone or a bone cavity, which are lined by endosteal cells. These spaces are occupied by red or yellow bone marrow (BM). Red BM facilitates active hematopoiesis, but with increasing age, the rate of hematopoiesis diminishes and more and more of it is converted to yellow BM —

consisting almost entirely of fat cells. However, under appropriate stimuli, such as extreme blood loss, yellow BM can convert to red BM again. In adults, red marrow is found mainly in the spongy bone of flat bones, such as iliac crest and sternum, and in the proximal ends of the long bones femur and humerus. Interestingly, these bones are relatively often affected by cancer metastasis, suggesting that red BM might be somehow involved ^{2,5}.




Figure 4 The basic multicellular unit. Bone is continuously remodeled by basic multicellular units (BMUs), the temporary anatomic structures that resorb bone and subsequently induce bone formation. Multinucleated osteoclasts (arrowhead) resorb the calcified matrix of a bone trabecula, the '*resorption phase*'. In a tight coupling, pre-osteoblasts migrate and differentiate into osteoblasts (empty arrowheads). These lay down new bone matrix, which is not yet calcified and is referred to as osteoid, the '*formation phase*'. Subsequently, the osteoid becomes mineralized. At the end phase of this remodeling, the surface of new bone is covered by flattened osteoblasts or 'lining cells' characterized by low/absent bone forming activity, the '*resting phase*'. Osteoblasts that are trapped in the matrix become osteocytes (arrow with empty arrowhead); others die or form new, flattened osteoblast or 'lining cells' (arrow). The number of BMUs can be modulated by mechanical loading, hormones and cytokines, marrow hematopoiesis and drugs (bone resorption inhibitors); adapted from ³⁴⁴.

Hematopoietic stem cells (HSCs) can reside in BM in two niches, the osteoblastic niche and the vascular niche (reviewed in ¹⁷⁶⁻¹⁷⁸). The osteoblastic niche is formed by endosteal osteoblasts that provide a quiescent environment for HSCs maintenance, support expansion of HSCs into the different hematopoietic lineages, and control HSC numbers ^{179,180}. In contrast, the vascular niche has been identified in association with fenestrated endothelium of sinusoids, and facilitates HSC transendothelial migration during mobilization or homing, dependent on endothelium-derived factors (Fig. 5) ^{177,178,181}.




Figure 5 Osteoblastic and vascular niche in bone. Under normal physiological conditions, HSCs reside in either the osteoblastic or vascular niche. In response to low levels of SDF-1 in the bone marrow, a portion of HSC daughter cells will leave the bone marrow and begin to mobilize and circulate. HSC homing is the reverse of mobilization, occurring in response to higher levels of SDF-1 in the bone marrow, particularly produced by the immature osteoblasts that align the periosteum. The osteoblastic niche may provide a quiescent microenvironment for HSC maintenance. In contrast, the vascular niche facilitates HSC transendothelial migration during mobilization or homing and may favor HSC proliferation and further differentiation. Higher oxygen concentration gradients as the cells progress from the osteoblastic niche to the vascular niche might play a role in recruitment, proliferation, and differentiation of HSCs/HPCs. Stress such as thrombocytopenia can induce HSCs to enter into the cell cycle, mobilize to the vascular niche, and differentiate. SNO, spindle shaped N-cadherin+ osteoblast; adapted from ¹⁷⁸.

Endothelial cells, osteoblasts, and other stromal cells constitutively express the chemoattractive cytokine, or chemokine, SDF-1 (alias CXCL12), while HSCs express its receptor CXCR4 ¹⁸². SDF-1 generated by endothelial cells induces HSCs from the circulation to undergo transendothelial migration mediated by E- and P-selectins ^{183,184}. Subsequently, HSCs could migrate toward the osteoblastic niche, where HSCs have been shown to adhere only to a subset of immature osteoblasts, the spindle-shaped N-cadherin+CD45⁻ osteoblastic (SNO) cells ¹⁸⁰. Accordingly, an increase of these SNO cells correlated with an increase in HSCs, suggesting that SNO cells function as key components of the osteoblastic niche ¹⁸⁰. Little is presently known about the molecules that define the vascular niche, and its relationship with the osteoblastic niche.

Granulocyte-macrophage colony stimulating factor (GM-CSF, alias CSF2) induces HSC and progenitor cell mobilization and is widely used clinically during stem cell-based transplantation procedures. The mechanism involved is a reduced concentration of SDF-1 in BM, whereas SDF-1 in the peripheral circulation is less affected after GM-CSF treatment¹⁸⁵. In bone marrow, GM-CSF induces proteolytic enzymes such as elastase, cathepsin G, MMP-2, and MMP-9, which inactivate SDF-1 and are required for cells to penetrate the endothelium¹⁸⁶. In addition, GM-CSF could regulate SDF-1 expression in osteoblasts at the transcriptional level^{187,188}.

4.3 TGF- β Superfamily

The TGF- β superfamily consists of more than 30 proteins in mammals, including TGF- β s, activins, BMPs, growth/differentiation factors and anti-Müllerian hormone (Fig. 6). These growth factors, and their antagonists, control many different biological processes such as proliferation, differentiation, apoptosis, and invasiveness in many different epithelial as well as non-epithelial cells¹⁸⁹⁻¹⁹². In mammals, three isoforms of TGF- β , i.e., TGF- β 1, TGF- β 2 and TGF- β 3, and more than 20 BMP-related proteins have been identified¹⁹³. In general, TGF- β isoforms have highly comparable structures and *in vitro* biological activities¹⁹⁴. In contrast, different BMPs often exert different, and even opposing, effects¹⁶¹. Therefore, they should be regarded as individual proteins rather than be classified as a group in respect to cell function.

TGF- β 1 is the most abundant isoform with the largest sources in platelets (20 mg/kg)¹⁹⁵ and bone (200 mg/kg)^{196,197}. In comparison, the sources of BMP2, BMP4, and BMP7 in bone are 21 mg/kg, 6 mg/kg, and 84 mg/kg, respectively¹⁷⁰.

The source of TGF- β /BMPs in the bone/BM microenvironment may be acellular, released by osteoclastic resorption of the extracellular bone matrix, or cellular, derived from cells that reside in bone (e.g., osteoclasts, osteoblasts, and osteocytes) or in bone marrow (e.g., megakaryocytes) (reviewed in¹⁹⁸).

4.4.1 Signaling Pathways

Members of the TGF- β superfamily mediate their pleiotropic effects by signaling through transmembrane serine/threonine kinase type I and type II receptors (Fig. 7)^{39,193,199}. The type II receptor kinases are constitutively active without ligand stimulation. Upon ligand-induced heteromeric complex formation between type II receptors and type I receptors, type I receptors become phosphorylated by the type II receptors and activate downstream signaling components among which Smad (Sma-Mad related protein) molecules proteins play a pivotal role^{193,200}. Unlike other members of the TGF- β superfamily, BMPs have a higher affinity for the type I receptor, rather than for the type II receptors^{201,202}. In mammals, five type II receptors and seven type I receptors have been identified^{39,161,203} (Table 2). The type II receptors include activin type II and type IIB receptors (ActRII and ActRIIB), TGF- β type II receptor (T β RII), BMP type II receptor (BMPRII) and anti-mullerian hormone type II recep-

tor (AMHRII). Type I receptors are termed activin receptor-like kinases (ALKs) 1 through 7. It is theoretically possible to form more than 30 different combinations of type II and type I receptors. However, under physiological conditions the combinations of type II and type I receptors appear to be limited by the variety of ligands that converge at the receptor level.




Figure 6 **Phylogenetic tree of TGF- β superfamily.** The phylogenetic tree is derived from protein alignment of the human, putative mature and fully processed forms. The length of the horizontal lines connecting one sequence to another is proportional to the estimated difference between the proteins. BMPs and TGF- β s are shown in black, other members of TGF- β superfamily in grey. AMH, anti-Müllerian hormone; BMP, bone morphogenetic protein; GDF, growth and differentiation factor; TGF- β , transforming growth factor- β ; based on ⁴¹⁵.

In most cell types, ALK5 (TGF- β type I receptor) is the predominant type I receptor that is activated by TGF- β through TBRII (Fig. 8) ²⁰⁴. ALK3 and ALK6 (BMP type IA and IB, respectively) are structurally highly comparable to each other and function as BMP type

I receptors for BMPs. In addition, BMP6 and BMP7 have also been shown to bind ALK2^{201,205}. Different BMPs bind with different affinity to the type I receptors, e.g., BMP6 and BMP7 binds with higher affinity to ALK2 and ALK6 than to ALK3^{201,206} (Fig. 8). The expression of ALK3, ALK6 and BMPRII was observed in normal and benign prostate tissue, and was found to correlate with low tumor grade (well-differentiated) in prostate cancer. In addition, loss of BMPRII expression correlated with poor prognosis in prostate cancer patients^{207,208}.




Figure 7 **General Mechanisms of TGF-β/BMP-induced Smad activation.** At the cell surface, a ligand (homo- or heterodimer) binds a complex of transmembrane receptor serine/threonine kinases (types I and II) and induces transphosphorylation of the GS segments (black) in the type I receptor by the type II receptor kinases. The consequently activated type I receptors phosphorylate selected Smads at C-terminal serines, and these receptor-activated Smads (R-Smads) then form a complex with the common Smad, Smad4. Activated Smad complexes translocate into the nucleus, where they regulate transcription of target genes, through physical interaction and functional cooperation with DNA-binding transcription factors (TF) and coactivators or repressors. Activation of R-Smads by type I receptor kinases is inhibited by Smad6 or Smad7. The E3 ubiquitin ligases Smurf1 and Smurf2 mediate ubiquitination and consequent degradation of R-Smads; based on¹⁹⁹.

Table 2 Type I and II receptors for TGF-β superfamily members in mammals. Alk, activin receptor-like kinase; ActRII and ActRIIB, activin type II and IIB receptors; TβRII, TGF-β type II receptor; BMPRII, BMP type II receptor.

Type I receptor	alias	Type II receptor
Alk1		BMPRII
Alk2	ActR1A	ActRII
Alk3	BMPRI1A	ActRIIB
Alk4	ActR1B	TβRII
Alk5	TβR1	AMHRII
Alk6	BMPRI1B	
Alk7		

Besides the signaling type I and type II receptor, several accessory type III receptors, are known, e.g., betaglycan (TBR111) ²⁰⁹ and endoglin (CD105) ²¹⁰. While endoglin inhibits TGF- β -induced ALK5–Smad3 signaling, it promotes BMP7–Smad1/Smad5 signaling ^{211,212}. On the other hand, betaglycan acts as a co-receptor for TGF- β that modulates the binding of TGF- β to its receptors, thus enhancing signaling via ALK5 ²¹³. Moreover, it can also function as a co-receptor for inhibin, disrupting activin and BMP signaling ²¹⁴.




Figure 8 Type I and II receptors, and R-Smads involved in BMP7 and TGF- β signaling. It is important to note that the presence of particular type I and II receptors, and R-Smads greatly differs in various cell types. † = activates only SMAD1 and -5, but not -8; § = BMP7 binds with low affinity to BMPRII/Alk3 complex; ‡ = pathway known in endothelial, but not epithelial, cells. Alk, activin receptor-like kinase; ActRII and ActRIIB, activin type II and IIB receptors; T β RII, TGF- β type II receptor; BMPRII, BMP type II receptor; based on data from ^{201,205,416-419}.

Smads, which are intra-cellular substrates for the TGF- β superfamily receptors can be subdivided into: 1) receptor-activated Smads (R-Smads) which include Smad2 and Smad3 for TGF- β and activin signaling, and Smad1, Smad5, and Smad8 for BMP signaling, 2) the common mediator Smad (Co-Smad), commonly referred to as Smad4, and 3) inhibitory Smads (I-Smads), which include Smad6 and Smad7 ^{39,193}. R-Smads contain a conserved SSXS phosphorylation motif in their very C-termini, of which the last two serine residues become phosphorylated following interaction with activated type I receptors ³⁹. Phosphorylation of R-Smads results in their heteromerization with Smad4 followed by nuclear translocation and regulation of gene transcription in association with other transcription factors ^{161,200}.

Smads are not equally activated by their cognate receptors. For example, ALK3 and ALK6 activate all three BMP R-Smads, whereas ALK2 can activate only Smad1 and Smad5, but not Smad8 ^{205,206}. Although Smad2 and Smad3 are structurally very similar to each other, Smad3 can directly bind DNA, whereas Smad2 signaling requires a specific combination of other transcription factors ²¹⁵. In fibroblasts, TGF- β -mediated induction of matrix metalloproteinase-2 (MMP-2) was selectively dependent on Smad2, whereas induction of c-fos,

Smad7, and TGF- β 1 autoinduction relied on expression of Smad3²¹⁶. Moreover, in tubular epithelial cells it was found that TGF- β -induced increases in CTGF and decreases in E-cadherin expression were Smad3-dependent, whereas an increase in MMP-2 expression was Smad2-dependent²¹⁷. In NMuMG mammary epithelial cells it was reported that complexes of Smad4 with both Smad2 or Smad3 can induce full EMT, however, the Smad3–Smad4 complex was most efficient³⁶.

Non-Smad pathways may also play an important role in understanding the diversity of signals generated by the TGF- β superfamily proteins. MAP (mitogen-activated protein) kinases, including ERK (extracellular-signal-related kinase), JNK (JunN-terminal kinase), and p38MAPK, can, among many other growth factors, also be activated by BMPs and TGF- β s in certain cell types. Moreover, signaling by Smads is modulated by various other signaling pathways allowing TGF- β superfamily ligands to elicit different biological responses in target cells (reviewed in^{193,199,200}).

4.4.2 Regulation of Activity

The level of activity of the TGF- β superfamily members is determined by the regulation of 1) bioavailability and 2) cellular signaling.

The bioavailability of TGF- β superfamily members is regulated by several types of mechanism, including proteolytic processing, secretion, interaction with ECM components, and extracellular binding proteins, and each step in the activation pathway is tightly controlled. For TGF- β and BMP7 post-translational processing is shown in figure 9^{198,218-222}. During transit through the rough endoplasmic reticulum, the signal peptide is removed from the pre-pro-protein and, following dimerization, another cleavage occurs by the convertase family of endoproteases²¹⁹. Within the secretory vesicles or in the extracellular space, these proteases cleave the precursor into a C-terminal mature peptide and an N-terminal precursor remnant, referred to as latency associated peptide (LAP) for TGF- β , and pro-domain for BMP7. Thus control and/or localization of convertase activity may represent an important level of regulation. After cleavage, mature TGF- β and LAP remain attached via non-covalent bonds to form the small latent complex (SLC). LAP shields the receptor interacting epitopes in the mature protein and this keeps TGF- β in its latent form²²³. The SLC can covalently attach to the large latent TGF- β -binding protein (LTBP) to form the large latent complex (LLC)^{224,225}. Most cell types secrete TGF- β as part of LLC, although some cells (such as the bone cell line UMR-106) secrete SLC²²⁶. Four different LTPBs have been identified, of which LTBP1, LTBP3 and, to a lesser degree, LTBP4 covalently bind to LAPs of all three TGF- β isoforms²²⁷. After secretion, LLC is targeted to ECM molecules, e.g., in the bone matrix. LTBP show remarkable homology with fibrillins, which are extracellular glycoproteins that are required for elastic fiber formation. Besides binding to ECM molecules, the C-terminal region of LTBP1 can also bind to the N-terminal region of fibrillin-1, linking LLC also to elastic microfibrils²²⁸.




Figure 9 TGF-β and BMP7 posttranslational processing. The mature BMP7 has three potential N-linked glycosylation sites, from which only the glycosylation sites at residue 372 in the TGF-β conserved domain region is heavily or completely glycosylated (*top of figure*: arrowhead). The signal peptide, which targets the proteins to the secretory pathway, is cleaved off during transit through the *rough endoplasmatic*

reticulum (RER). Subsequently, two monomers dimerize by way of disulfide bridges between cysteine residues. The protein is cleaved by subtilisin-like proprotein convertases (SPCs) at the RXXR motif. This yields the prodomain, or latency associated protein for TGF- β , and the mature peptide. This mature peptide stays noncovalently associated with its prodomain, forming the soluble BMP7 complex for BMP7 or the small latent complex (SLC) for TGF- β . The noncovalent association prevents the premature activation of mature TGF- β . The SLC can become covalently attached to a Large Latent Binding Protein (LTBP) to form the Large Latent Complex (LLC), and the SLC to LLC ratio depends on the cell type. After its secretion, the LLC is directed to fibrillin-1 and/or the ECM and stored through binding of the LTBP with these components. Inflammatory proteolytic enzymes, including elastase, release LLC from fibrillin-1, and several proteases, such as plasmin, mast-cell chymase and thrombin, release LLC from the ECM. The SLC is more readily available for activation, and can be activated by proteases or conformational change in the LAP induced by interaction with, e.g., thrombospondin or integrins. The pro-domain of BMP7 targets the soluble BMP7 complex to the fibrillin-1 and -2 in the extracellular matrix. The precise mechanisms of posttranslational processing are less well understood for BMP7 and remains to be elucidated. Based on data from ²¹⁹⁻²²¹ (BMP7) and ^{198,222} (TGF- β).

In order to exhibit their biological activity, the latent TGF- β complexes need to be released from microfibrils and ECM. A recent study revealed that LLC release can be initiated by the displacement of LTBP bound to fibrillin-1 ²¹⁸. Degradation of microfibrils by inflammatory proteolytic enzymes (such as elastase) releases fragments of fibrillin-1, including an internal fibrillin fragment that efficiently binds to the N-terminal region of fibrillin-1 and displaces LTBP, releasing LLC from microfibrils ²¹⁸. The release of LLC from the ECM in bone and other tissue is mediated by several proteases, including plasmin, mast-cell chymase and thrombin (reviewed in ^{198,222}).

Subsequently, the truncated LLC and SLC can be subjected to three different mechanisms of *in vivo* activation: 1) degradation of the latency-associated peptide (LAP) by proteases, 2) induction of a conformational change in the LAP, e.g., by interaction with integrins and thrombospondin, and 3) rupture of the noncovalent bonds between LAP and mature TGF- β ²²³. In contrast, the soluble BMP7 complex — consisting of the mature peptide and its noncovalently associated prodomain — is already active, and is targeted to fibrillin-1 and -2 ²²⁰. Therefore, it may be that proteases, such as elastases, are critically involved in the release of the soluble BMP7 complex from the elastic microfibrils. However, the precise mechanisms of post-translational processing, secretion and interaction with ECM components are less well understood for BMP7 and remain to be elucidated.

In contrast, extracellular BMP antagonists are relatively well-studied secreted peptides that bind BMPs with high affinity and prevent their interaction with their cognate receptors. These antagonists can be categorized into subgroups, i.e., noggin ²²⁹, twisted gastrulation protein ²³⁰, the chordin family ²³¹, and the DAN family ²³².

TGF- β /BMP signaling is limited by 1) dominant negative non-signaling membrane pseudoreceptors, 2) I-Smads, 3) ubiquitination and proteasomal degradation of signaling effec-

tors, 4) corepressors, and 5) phosphorylation of the linker region of R-Smads (reviewed in ^{233,234}). Many of the negative regulators involved are potentially induced by BMP/TGF- β signaling, and may thus participate in a negative feedback loop to control the intensity and duration of TGF- β signaling ²³⁵⁻²³⁹. The pseudoreceptor BAMBI (BMP and activin membrane-bound inhibitor) is a truncated, kinase-deficient, type I receptor that binds to ligand competitively and thereby inhibits BMP and TGF- β signaling ²⁴⁰.

The I-Smads, Smad6 ^{237,241} and Smad7 ²⁴², inhibit signal transduction by interference with the activation of R-Smads and prevention of heterodimerization between R-Smads and Smad4. In addition, I-Smads can also interact with type I receptors through Smurfs (Smad ubiquitin regulatory factors), inducing ubiquitination and degradation of the activated receptor complexes ²⁴⁴⁻²⁴⁷. The Smurf1/2-Smad7 complexes play an important role in regulating ubiquitination of TGF- β receptor complexes ²⁴⁸⁻²⁵⁰, Smurf1-Smad6/7 complexes appear to target BMP receptor complexes for degradation ²⁴⁷. So, whereas Smad7 acts as a general inhibitor of TGF- β superfamily member signaling pathway (BMP and TGF- β), Smad6 preferentially blocks BMP signaling ^{236,237,241-243}.

TGIF (TGF- β -induced factor) is a transcriptional corepressor, i.e., a Smad binding protein that interferes with the ability of Smads to bind coactivators. It binds Smad2 and -3, thereby preventing the interaction of Smads with coactivators, resulting in reduced target gene expression. The competition for Smad binding between coactivators and corepressors determines the magnitude of the transcriptional output from a given level of signaling. Sloan-Kettering retrovirus (Ski) and its relative Ski-related novel gene N (SnoN) ^{251,252} are also corepressors, which suppress Smad signaling by associating with the MH2 binding domain of Smads. Both Ski and SnoN bind Smad2 and -3, thereby inhibiting TGF- β signaling ^{238,251-254}. In addition, Ski, but not SnoN, can also interact with Smad1 and -5 and antagonize BMP signaling ^{251,255-257}. By interacting with Smad1, -5, -6, -7, and -8, the transducer of ErbB-2 (Tob) also represses BMP signaling ^{258,259}.

Inhibition of the Smad pathway can also occur via growth factor induced phosphorylation of the linker region of R-Smads, reducing ligand-induced nuclear accumulation of R-Smads. Activation of Erk by EGF and HGF, or activated Ras can induce this phosphorylation ²⁶⁰⁻²⁶².

4.4.3 Physiologic and Pathophysiologic Functions

BMPs are paradigmatic molecules directly regulating osteoblast generation and were first identified by their ability to form new bone *in vivo* (reviewed in ^{161,263}). They play a crucial role in skeletal and joint morphogenesis, bone remodeling, and fracture repair by inducing proliferation, lineage determination, differentiation, and apoptosis in chondrocyte and osteoblast precursors ^{203,264}. Subsequently, they were shown to act as multifunctional regulators of embryonic patterning and organogenesis, tissue remodeling, and repair ²⁶⁵.

BMPs have also been implicated in cancer development. Elevated levels of BMP6 are associated with higher grade primary tumors and advanced prostate cancer with metastasis.

sis^{266,267}, and BMP2 induces migration and invasion in breast²⁶⁸ and prostate²⁶⁹⁻²⁷¹ cancer cells. BMP7 regulates multiple cellular processes including cell proliferation, migration, and apoptosis. In cells from the osteoblast lineage, exogenous addition of BMP7 can result in inhibition or stimulation of cell proliferation, totally dependent on the cell line type^{272,273}. In PC-3 and DU 145 prostate cancer cells, BMP7 inhibited cell proliferation by arresting cells in G1 phase via up-regulation of the cyclin-dependent kinase (Cdk)-inhibitors. However, in C4-2B prostate cancer cells, BMP7 promotes cell survival by inhibiting stress-induced apoptosis via both the Smad/survivin and c-jun NH2-terminal kinase pathways²⁷⁴.

Yet a different function for BMP signaling was demonstrated when Zhang and co-workers demonstrated that conditional deletion of ALK3 (BMPRIA) lead to increased numbers of SNO cells and subsequently to higher HSC numbers. Thus BMP signaling via ALK3 complex controls the number of HSCs by regulating the niche size¹⁸⁰.

TGF- β is a potent growth inhibitor in normal and non-malignant epithelial cells^{32,33}. However, different types of carcinomas often escape this tumor-suppressing activity and become refractile to growth inhibition^{33,111,275}. In fact, TGF- β can potentiate tumorigenesis and contribute to the progression and invasiveness of various carcinomas by inducing EMT³⁴⁻³⁸. Accordingly, it has been shown that a blockade of TGF- β (signaling) inhibits tumor cell viability, migration, and metastasis²⁷⁶⁻²⁷⁹. Moreover, TGF- β stimulates the PTHrP production in metastatic cancer cells, thereby being an important mediator in lytic bone destruction (as discussed in more detail in the paragraph 5.2.1, 'Osteolytic Bone Metastasis').

Although some BMPs, such as BMP2²⁸⁰ and BMP4²⁸¹, have also been shown to induce an EMT in certain cell types under specific conditions, the homodimeric protein BMP7 can induce the opposite, a mesenchymal-to-epithelial transition (MET) in normal and non-transformed cells^{192,282}. For instance, during kidney development, BMP7 is essential for the condensation and epithelialization of the metanephric mesenchyme in the kidney, resulting in the formation of the tubular epithelium^{95,96,98}. In the adult kidney, BMP7 appears to be involved in the preservation of the epithelial phenotype of renal tubular cells²⁸³, and inhibition of fibrosis^{284,285} and inflammation^{286,287}. Moreover, BMP7 treatment partly inhibited the pathologic effects in experimentally induced acute²⁸⁷ and chronic^{284,288,289} kidney disease, including its complications renal osteodystrophy^{290,291} and vascular calcification²⁹². In clinical practice, BMP7 is used as an osteoinductive agent in treatment of non-union fractures²⁹³.

5 'Seed-Soil' Interactions

The establishment of a metastasis is dependent on the reciprocal interactions between cancer cells and the microenvironment. In order to form an overt bone metastasis, cancer cells first have to extravasate into, colonize and then grow in, the BM. Thus, the first interaction between the 'seed' and the 'soil', is when circulating cancer cell in blood interact with the endothelium of a specific tissue²⁹⁴. In most tissues, the endothelium differs in surface

markers, morphological phenotype and specialized functions²⁹⁵, and is still susceptible to further modification by specific stimuli, such as inflammation. The specific combination of chemoattractive and adhesion molecules on the endothelium in the BM has been demonstrated to be particularly favorable for the retention and extravasation of circulating cancer cells²⁹⁴.

As discussed in paragraph 4.2, BM endothelium-derived SDF-1 induces CXCR-4 expressing HSCs to undergo transendothelial migration mediated by E- and P-selectins^{183,184}. Similarly, metastatic prostate cancer cells that adhere specifically to BM endothelial cells have also been reported to make use of E-selectin ligands for entry into BM²⁹⁶⁻²⁹⁸. Moreover, the chemokine receptors CXCR4 and CCR7 are also expressed by a variety of osteotropic epithelial cancer cell types²⁹⁸⁻³⁰¹, also mediating their adhesion to BM endothelium.

OPN, BSP, and type I collagen are major components of mineralized bone. These proteins mediate local adhesion, motility, survival and growth by interactions with matrix adhesion molecules, namely integrins, and are expressed by several types of cells, including HSCs. Similarly, cancer cell adhesion to OPN, BSP and type I collagen is also integrin-dependent^{167,168}. So, integrin expression may not only be critical for guiding HSC to hematopoietic sites, but also for BM colonization by cancer cells³⁰². Mainly the $\alpha v\beta 3$ (alias vitronectin receptor) and $\alpha IIb\beta 3$ integrins seem to participate in determining the osteotropism of cancer cells³⁰³⁻³⁰⁶. Accordingly, the MDA-MB-231-B02 breast cancer cell line, which is a subclone of MDA-MB-231 (MDA-231), constitutively overexpresses $\alpha v\beta 3$ integrin and only metastasizes to bone³⁰⁷. Similarly, *de novo* expression of $\alpha v\beta 3$ integrin in 66cl4 breast cancer and CHO ovarian cancer cells that metastasize to lungs, but not to bone, is sufficient to promote their dissemination to bone^{307,308}. Moreover, $\alpha v\beta 3$ integrin was shown to cooperate with BSP, MMP-2 and -9 in promoting osteotropic cancer cell invasion^{309,310}. CD44 is a non-integrin, ubiquitous and multifunctional surface adhesion molecule, which has been identified as a receptor for both the glycosaminoglycan hyaluronan and OPN. It is expressed by various cancer cell types and has a well-established role in skeletal metastasis³¹¹. Taken together, the bone/BM microenvironment is able to actively allow circulating cancer cells to preferentially arrest in, extravasate into, and colonize BM, adopting similar pathways that are used by the homing of normal HSC to the bone/BM microenvironment³¹².

Besides high affinity for bone matrix, breast and prostate cancer cells can also produce bone matrix proteins such as OPN, osteonectin³¹³, and BSP³¹⁴. This acquisition of bone cell-like properties by tumor cells, is called *osteomimicry*^{313,315,316}, and improves homing, adhesion, proliferation, and survival in the bone/BM microenvironment.

According to the 'Seed and Soil' hypothesis, interaction between tumor cells and the microenvironment is supposed to occur only after tumor cells reach the microenvironment. However, this classical 'Seed and Soil' hypothesis appears to be too simplistic, since the recent discovery of the so-called *pre-metastatic niche* (PMN)³¹⁷. Kaplan and co-workers showed that VEGFR1⁺ BM-derived hematopoietic progenitor cells (HPCs) were mobilized by

factors secreted from primary tumors (melanoma and lung carcinoma) to form fibronectin-rich patches in (non-bone) target organs. Remarkably, these niches are formed prior to the arrival of metastatic tumor cells. Blocking the PMN formation by VEGFR1 antibodies significantly inhibited metastasis. Strikingly, the PMN was shown to dictate the metastatic pattern, since conditioned media from a melanoma cell line could redirect lung carcinoma cells to metastatic sites that are favored by melanoma, but not lung cancer. Two cytokines produced by primary tumors, VEGF and placental growth factor (PlGF), were suggested to mediate the formation of the PMN, although additional chemokines or growth factors are certainly necessary to facilitate different organ-specific metastasis^{317,318}. In summary, the PMN-model indicates that long range communication between tumor cells and target organs can occur before the arrival of tumor cells at distant sites. Understanding the molecular mechanisms involved in the formation and maintenance of PMNs and normal HSC niches (osteoblastic and vascular) and their role in supporting organ-specific metastasis may provide new approaches for developing novel treatment strategies. However, it remains to be investigated whether the PMN-model is also applicable to other types of cancer, including breast and prostate cancer.

5.1 Bone Turnover and Skeletal Metastasis

The rate of bone turnover is closely associated with the number of sites with increased paracrine availability of growth factors due to osteoclastic bone resorption, and, accordingly, the probability that the cancer cell (the 'seed') will find a favorable 'soil' in the bone/BM environment. The latter part of this hypothesis is based on experimental studies, which have shown that the rate of bone turnover is associated to the occurrence and progression of bone metastases indicating that the growth support provided by the bone microenvironment is active during bone resorption³¹⁹⁻³²¹ (see 'Osteolytic Bone Metastasis'). Recently, this view was further substantiated by clinical studies, showing a strong and highly significant association between the rate of bone resorption and incidence of subsequent skeletal complications in breast and prostate cancer patients³²²⁻³²⁵.

Serum alkaline phosphatase (sALP) and urinary hydroxyproline are common and non-expensive markers of bone formation and bone resorption, respectively. They are useful tools for assessing the overall bone turnover rate in cancer patients at risk to develop bone metastasis. Recently, more sensitive and specific biochemical markers have become available. Immunoassays for bone-specific alkaline phosphatase and type I collagen propeptides are currently the most sensitive markers for assessing bone formation. Best indices of bone resorption are the immunoassay for the pyridinoline cross-links and the related peptides that can be measured in urine and serum³²⁶. These markers for bone turnover may be useful in planning the rational use of preventive treatment with bone resorption inhibitors as will be discussed in more detail in paragraph 7, 'Treatment of Bone Metastasis'.

5.2 Bone Metastatic Phenotype

Whereas prostate cancer predominantly elicits an osteoblastic response resulting in osteosclerotic lesions, breast, lung and kidney cancer preferentially trigger an osteoclastic reaction mainly resulting in osteolytic lesions (reviewed in ^{18,22}). Although an osteolytic lesion is dominantly destructive, there is usually also a local bone formation response, which presumably represents an attempt at bone repair. Moreover, up to 25% of patients with bone metastases from breast cancer also have blastic lesions that are similar in appearance to those from patients with metastatic prostate cancer, and vice versa, some prostate cancer patients have osteolytic lesions that are similar in nature to those seen in patients with metastatic breast cancer. In other words, the common concept that there are basically two types of bone metastases, should rather be replaced by a view that the type of lesion is the result from a (dis)balance between anabolic and catabolic factors.

With regard to bone integrity, bone regions affected by either osteolytic or osteosclerotic lesions are both more prone to pathological fractures due to architectural distortion and deposition of bone of the woven (immature or embryonic) type, which is much less mechanically competent than the lamellar (mature) type.

An increase in the RANKL to OPG ratio is one of the major determinants of an osteolytic phenotype, and vice versa, a decrease in the ratio is a major determinant of an osteoblastic phenotype (reviewed in ^{146,327}).

5.2.1 Osteolytic Bone Metastasis

In osteolytic bone metastases, the destruction of bone is mediated by osteoclasts, as could histologically be observed by the numerous osteoclasts eroding the relatively scarce bone matrix ^{328,329}.

PTHrP is regarded as the main mediator of osteoclast activation in bone metastatic breast cancer ^{18,20}. PTHrP induces RANKL and downregulates OPG in cells of the osteoblast lineage ³³⁰. It is produced by most solid osteotropic cancers ^{331,332}, and plays a major role in the development of the osteolytic features of their bone metastatic lesions ³³³. Furthermore, PTHrP is considered to be responsible for the humoral hypercalcemia of malignancy (reviewed in ²⁰). In breast cancer 90% of metastases in bone were found to express PTHrP, compared to only 17% at non-bone sites and 60% of the primary tumors ^{331,334}. Initially, expression of PTHrP in the primary tumor appeared to be associated with formation of bone metastases ^{335,336}. However, a large prospective study of 526 consecutive patients with operable breast cancer demonstrated the opposite, PTHrP expression in primary breast cancer was significantly associated with fewer (bone) metastases ^{337,338}. Therefore, the most likely explanation for the observed increased PTHrP expression in bone metastases ^{334,339}, is that the bone microenvironment induces cancer cells to express PTHrP rather than cancer cells that metastasize to the bone have an intrinsically higher PTHrP expression.

The hypothesis that PTHrP is induced by the bone microenvironment is also substantiated

by experimental evidence from Yin and co-workers demonstrating that PTHrP production in MDA-231 breast cancer cells was stimulated by TGF- β ³⁴⁰. Accordingly, introduction of a TBR11 lacking a cytoplasmic domain (TBR11Dcyt) that exhibited dominant-negative effects into these cells prevented an increase in PTHrP production in response to TGF- β . Moreover, in an experimental model of bone metastasis (see paragraph 6, 'Animal Models of Bone Metastasis'), mice receiving MDA-231 cells lacking TGF- β signaling had fewer and smaller osteolytic lesions than mice inoculated with parental or empty vector-transfected cells. Taken together, PTHrP increases osteoclastic bone resorption with consequent release and activation of matrix-integrated growth factors, especially TGF- β and IGFs, stimulating both tumor growth and further secretion of PTHrP, thus establishing a 'vicious cycle' (Fig. 10).




Figure 10 The vicious cycle of the osteolytic bone metastasis. Release of osteolytic factors, such as parathyroid hormone-related protein (PTHrP), by bone metastatic breast cancer cells causes nearby osteoblasts to change the mix of signals that they release: they increase RANKL synthesis. RANKL induces osteoclast precursors to mature into functional osteoclasts. The latter undertakes osteolysis, which causes bone demineralization, exposes the extracellular matrix within the bone, and results in liberation of various growth factors, including TGF- β , IGFs, BMPs, PDGF. These growth factors cause cancer cell proliferation and survival, and the additional presence of TGF- β stimulates production of PTHrP by the cancer cell, resulting in a self-sustaining positive-feedback loop that has been termed the 'vicious cycle' of osteolytic metastasis.

In addition to PTHrP, RANKL expression on osteoblasts/stromal cells can be upregulated by many other tumor secreted factors such as IL-1, IL-6, IL-8, IL-11, and tumor necrosis factor (TNF)- α . In addition, these osteolytic factors are also capable of modulating osteoclas-

togenesis independent of RANKL (reviewed in ³⁴¹). For example, IL-8 was shown to directly bind to CXCR1 present on osteoclast precursors ³⁴². More recently, the intra-cellular component NF- κ B was demonstrated to play a crucial role in osteolytic bone metastases from breast cancer ³⁴³. GM-CSF (alias CSF-2) was identified as the key target of NF- κ B that mediates osteolytic bone metastasis of breast cancer by stimulating osteoclast development, thereby identifying new potential targets for prevention and treatment of skeletal metastasis from breast cancer.

The concept of the 'vicious cycle', in which cancer cells express osteolytic factors under influence of growth factors that are released from the bone matrix, has important therapeutic consequences: inhibition of bone resorption may interrupt this vicious cycle and thus may preserve bone mass, prevent pathological bone fractures, and even arrest tumor progression in the bone metastasis.

5.2.2 Osteosclerotic Bone Metastasis

Compared to osteolytic bone metastasis, mechanisms determining the exaggerated response in osteosclerotic bone metastasis are still poorly understood. It is believed that the excess production of mineralized bone matrix adjacent to the metastatic tumor cell deposit is due to an increased secretion of factors inducing proliferation, differentiation, and recruitment of osteoblast progenitors by the metastatic cancer cells (Fig. 11) (reviewed in ^{18,21,22,344}). Nonetheless, markers of bone resorption are also increased in metastatic prostate cancer, accurately reflecting the extent of disease progression ^{322-325,345}. In fact, bone resorption markers are even more elevated than in patients suffering from lesions from breast cancer ³²⁵, providing the rationale for treatment with bone resorption inhibitors, such as bisphosphonates, in prostate cancer patients (see paragraph 7.1.1, 'Bone Resorption Inhibitors').

BMPs are paradigmatic molecules that directly regulate osteoblast proliferation and differentiation (reviewed in ²⁴³). Both normal and neoplastic human prostate tissue have been shown to express a variety of BMPs, namely BMP2, BMP3, BMP4, BMP6, and BMP7 ³⁴⁶. Therefore, BMPs have been postulated to play an important role in the etiology of the osteoblastic phenotype of bone metastasis. Indeed, prostate cancer secreted BMPs in culture media were shown to promote mineralization *in vitro* (potency from high to low: BMP6 > BMP7 > BMP4) ³⁴⁷. Moreover, forced overexpression of noggin — a BMP2, -4, -6, and -7 antagonist — in osteoinductive cell lines abrogated the osteoblastic response *in vivo* ^{270,348}, however, tumor progression was not significantly affected ^{270,348}. Direct experimental evidence that a specific BMP could affect the osteoblastic response was provided by using neutralizing BMP6 antibodies, which inhibited the blastic response ²⁶⁹.

Prostate and breast cancer cells express a variety of Wnt proteins, which can enhance bone mass ³⁴⁹. Interestingly, in breast cancer and myeloma — characterized by osteolytic lesions with suppression of osteoblastic activity — Wnt signaling is inhibited by the extra-




Figure 11 Pathophysiology of osteosclerotic bone metastasis. Release of endothelin (ET-1) and different Wnts by bone metastatic prostate cancer cells causes nearby osteoblasts progenitors to differentiate into osteoblasts. Mature osteoblasts also secrete growth factors such as TGF- β that may stimulate bone metastatic growth. Therefore, a 'vicious cycle' is also considered to occur in osteoblastic metastasis.

cellular Wnt-antagonist dickkopf (DKK-1) expressed by the tumor cells^{348,350,351}. Moreover, *in vitro* differential expression analysis in breast and prostate cancer cell lines showed that the expression of the Wnt and BMP antagonists, DKK-1 and noggin, respectively, rather than expression of Wnts and BMPs determines the manifestation (blastic/lytic) of the bone metastasis³⁴⁸.

Other factors that have also been implicated as direct stimulators of osteoblast recruitment, proliferation, and differentiation in osteosclerotic bone metastases are IGF-I and -II, FGF-1 and -2, VEGF, platelet derived growth factor (PDGF-BB), and TGF- β ^{346,349,352}.

Prostate cancer patients with osteoblastic metastases have high serum levels of endothelin-1 (ET-1)³⁵³. Besides being a potent vasoconstrictor, ET-1 is also a direct mitogen for osteoblast progenitors³⁵⁴. A causative role for ET-1 in the pathophysiology of osteosclerotic bone metastasis has been demonstrated in pre-clinical models from prostate^{354,355} and breast cancer³⁵⁶. The inhibition of bone metastatic but not primary tumor growth by treatment with ET-1-selective receptor antagonists in pre-clinical models suggests that a vicious cycle may also occur in osteoblastic metastasis³⁵⁶.

In addition to factors that directly affect osteoblasts, prostate cancer cells also produce factors that indirectly affect osteoblast function by modifying the bone microenvironment, such as VEGF, and the proteases urokinase-type plasminogen activator (uPA) and prostate-specific antigen (PSA)³⁵². uPA stimulates osteoblast proliferation, probably by hydrolyzing IGF-binding proteins and thereby increasing free IGF levels³⁵⁷. PSA is a serine protease of

the kallikrein family and a well-known marker of prostate cancer progression. It can cleave IGF-binding protein (IGFBP)-3, thereby reducing the ability of IGFBP-3 to antagonize the effects of IGF-I³⁵⁸. In addition, PSA can cleave PTHrP, thus allowing the osteoblastic reaction to predominate by decreasing bone resorption³⁵⁹.

In conclusion, tumor cells (the 'seeds') can accomplish metastases only in the organs where the microenvironment (the 'soil') is permissive for their growth, i.e., reciprocal interaction between the bone/BM microenvironment and cancer cells is fundamental for establishing bone metastatic growth. Subsequently, the reciprocal interaction can result in exaggerated stimulation of bone degradation and/or formation, ultimately determining the bone metastatic phenotype.

6 Animal Models of Bone Metastasis

In clinical studies, the possibility to manipulate different variables is, obviously, very limited. Therefore, animal models have become important tools to investigate the pathogenesis of bone metastasis as well as to develop novel therapeutic strategies. In general, the incidence of bone metastases from spontaneous breast and prostate cancer in rodents and non-human primates is extremely rare. So, bone metastases in animal models need to be induced experimentally. These include syngeneic transplantation of spontaneously occurring rodent cancers and xenograft models with tumors or cell lines derived from human cancers into immunodeficient rodents (e.g., nude mice and rats, and severely compromised immunodeficient (SCID) mice). Furthermore, newly developed transgenic mice and immunodeficient mice transplanted with human bone fragments have been actively pursued as alternative models (reviewed in^{360,361}).

6.1 Spontaneous Mammary and Prostate Cancer in Animals

Benign and malignant mammary neoplasms frequently develop in rats and mice, and the incidence is dependent on the strain. Unfortunately, these may not be good models for human disease. Most spontaneous mammary carcinomas in mice and rats have mild local tissue invasion, with low incidence of spontaneous metastasis to regional lymph nodes or lungs, and bone metastases are very rare. Moreover, spontaneous tumors can have long latency-periods. Compared to breast cancer, the incidence of prostate cancer in rodents and non-human primates is very rare³⁶². However, specific strains of rats exist that have increased incidence of prostate neoplasia, but again, the incidence of bone metastasis formation is very rare^{363,364}. Spontaneous prostate cancer occurs most commonly in dogs, including the formation of osteoblastic bone metastases³⁶².

6.2 Transgenic Induction of Mammary and Prostate Cancer in Mice

Mutations introduced in the genome — e.g., in the tumor suppressor p53 — by genetic engi-

neering have yielded transgenic mice that are prone to spontaneous development of a variety of neoplasms³⁶⁵. Tumors arising specifically in the mammary or prostate gland can be accomplished using oncogene expression — such as SV40 large T antigen — driven by tissue selective promoters. The whey acidic protein, C(3)1, and MMTV promoters are often used for the mammary gland³⁶⁶, whereas the probasin, C(3)1, PSP94 and PSA promoters are used for the prostate gland³⁶⁷. Similarly, tissue-specific inactivation of (tumor suppressor) genes using the Cre/loxP site-specific recombination system could also result in tissue-specific carcinogenesis, as was shown by inactivation of p53 and E-cadherin genes³⁶⁸. The advantages of transgenic models of cancer include their predictability and the autochthonous development of cancer, i.e., originating where normally found. The disadvantage of the transgenic models is the low incidence of metastasis often due to rapid progression of the primary neoplasm. Moreover, in the transgenic models that do metastasize, metastases are usually found in lungs, but not in other organs such as bone²⁷⁷.

6.3 Syngeneic and Xenograft Models of Bone Metastasis

Compared to transgenic mice, one of the major advantages of both syngeneic and xenograft models — using cancer cells and mice with an identical or different genetic background, respectively — is that cancer cells can be relatively easily subjected to genetic engineering *ex vivo*. In addition, these models also facilitate selection of cancer cell lines that have specific properties, such as a high propensity to spread to bone. These cell lines can be grown *in vitro* and, subsequently, re-injected intravenously, intracardially, orthotopically, or directly into the BM cavity. It is important to keep in mind that with respect to immunology, the use of immunocompetent mice in the 4T1 and other syngeneic models is preferred over xenograft models, which uses immunodeficient mice. On the other hand, cancer cells in the syngeneic model are not of human origin which may also lead to pitfalls when translating to the human situation.

6.3.1 Routes of Cancer Cell Inoculation

In syngeneic and xenograft experimental bone metastasis models, three major routes of cancer cell inoculation are commonly used, including 1) direct injection into bone microenvironment, 2) systemic injection, particularly intracardially, and 3) injection at orthotopic sites.

Cancer cells can be injected locally adjacent to a bone surface³⁶⁹ or into a marrow cavity^{370,371} (this thesis, chapter 2–6) to create an animal model for tumor growth in the bone microenvironment. However, local injection of tumor cells does not represent the entire process of bone metastasis and there can be distortions from injection caused by the injury to the bone (environment). Therefore, orthotopic or systemic injection is preferred.

Arguello and co-workers were the first who systemically injected cancer cells directly into the left ventricle of the heart³⁷². Subsequently, cancer cells are dispersed throughout

the whole body, and metastases only develop in particular organs, i.e., reciprocal interaction between the cancer cell (the 'seed') and the microenvironment (the 'soil') is fundamental for establishing metastatic growth. The original model used immunocompetent mice, but later models used immunocompromised mice. At present, this technique has been adopted by many research groups using different types of cell lines, including the PC-3M-Pro4 prostate cancer cell line³⁷³ (this thesis, chapter 7) and the broadly used MDA-231 breast cancer cell line^{66,333,374,375} (this thesis, chapter 4,6). When MDA-231 wild type cells are intracardially injected into young (4–6 weeks old) female nude (or SCID) mice, metastases develop in specific organs, including bone. In this model, bone metastases can be clearly monitored by radiography after 3–4 weeks. Histologically, numerous osteoclasts and aggressive tumor colonization can be detected^{66,333,374,375}. Bone metastases occur particularly in the metaphyses of the long bones, which are sites of active bone modeling and remodeling in young mice. Active bone turnover, high blood flow, and fenestrated sinusoids at these sites may predispose the metaphyses to the development of tumor growth. Blood vessels at the metaphyses have 180° turns and are common sites for embolization in young animals. Therefore, the anatomic arrangement of blood vessels in metaphyses may predispose to tumor cell embolization and development of bone metastases in growing rodents³⁷⁶. One of the disadvantages of the intracardiac injection model is that it lacks the critical early steps occurring between early growth at the primary site and entry into the circulation.

Kuperwasser and co-workers have developed an orthotopic xenograft model in which both the stromal and epithelial component of the reconstructed mammary gland are of human origin, enabling to genetically modify both epithelial and stromal cells *ex vivo*. They demonstrated that an altered stromal environment — stromal cells overexpressing TGF- β or HGF — promoted breast cancer progression³⁷⁷. However, this model as well as other orthotopic models — including syngeneic and xenograft models — rarely show involvement of bone metastases. An exception is the 4T1 syngeneic model, in which orthotopic injection of 4T1 murine breast cancer cells results in formation of a primary tumor that disseminates to lung, adrenal glands, and bone^{378,379}. Even more, syngeneic as well as xenograft models facilitate selection of sublines of cancers *in vivo* that have an increased incidence of bone metastasis after injection *in vivo*. For example, the 4T1.2 subclone of the 4T1 subline has an increased incidence of metastasis to bone after re-injection into the mammary fat pad³⁷⁸.

Alternatively, experimental models can also use tumor tissue instead of tumor cells. Tumor tissue can be generated by implanting human cancer cell lines subcutaneously in nude mice, resulting in hybrid tumors containing a mixture of human cancer cells and murine stroma and blood vessels. Implantation of such a hybrid tumor, containing human MDA-MB-435 breast cancer cells, into the mammary glands of nude mice resulted in formation of bone metastases³⁸⁰.

Human prostate cancer cell lines have also been transplanted orthotopically in mice, successfully representing different stages of cancer progression *in vivo* ranging from

androgen-dependent growth, androgen-independent growth to metastatic growth, including formation of osteoblastic bone metastases³⁸¹⁻³⁸³.

6.4 Subcutaneous Transplantation of Human Bone

Human fetal bone has been transplanted successfully to the subcutis of immunodeficient SCID mice to serve as a preferential site of metastasis of human prostate cancer cells injected into the left ventricle of the heart or as a site of tumor growth after local injection of cancer cells near the viable bone substrate³⁸⁴. Similar results were also reported with the use of adult human bone in SCID mice³⁸⁵. Similarly, orthotopic injection of a specific human breast cancer cell line, SUM1315, into SCID mice resulted in metastasis to the engrafted human bone, and not to mouse skeleton³⁸⁶. Hence, these models demonstrated a preferential selection of human cancer cells to localize and proliferate in human bones compared with mouse bones. Furthermore, it was very recently demonstrated that SUM1315 cells were also able to metastasize to tissue-engineered bone, manufactured by BMP2-stimulated human BM stromal cells on a silk scaffold *in vitro*³⁸⁷.

6.5 *In Vivo* Imaging

Studying bone metastasis in small animal models has often relied on histological analyses, PCR amplification, and radiography. However, assays that utilize excised tissues are subject to sampling limitations and cannot assess the overall extent of disease in a given animal. To overcome this limitation, *in vivo* detection of bone metastases using high-resolution Faxitron radiography has been used in an attempt to provide temporal information. However, it does not detect micrometastatic lesions, the desired targets for therapeutic intervention, or the actual tumor burden. Therefore, newer imaging modalities — e.g., based on the optical imaging — need to be developed and utilized to improve detection and quantification bone metastases in animal models^{388,389} (this thesis, chapter 3).

7 Treatment of Bone Metastases

Once patients show evidence of bone metastasis, the disease is incurable with currently available therapies. At present, therapies focus on symptomatic management and limiting the progression of established disease (reviewed in^{17,18}). Therefore, the ultimate goal is to develop new and better treatment strategies that can either prevent or treat bone metastases. For this we need a better understanding of which processes are crucially important in the formation and development of bone metastases.

7.1 Treatment Strategies

The selection of the appropriate systemic anti-tumor treatments, hormone and cytotoxic treatments, that are presently given are very much dependent on the type of cancer. In addition,

external beam radiotherapy can provide excellent palliation for localized metastatic bone pain, which can be achieved with a short treatment schedule of one to five fractions in most clinical situations³⁹⁰. Radiopharmaceuticals are now also available for the palliation of metastatic bone pain, with Strontium-89 as an effective wide-field radiotherapeutic in prostate cancer³⁹¹.

7.1.1 Bone Resorption Inhibitors

Other treatment strategies for bone metastatic disease are based on the interference with the bone microenvironment and the concomitant release of growth factors from mineralized bone during bone resorption that may support bone metastatic growth. Differently from most other tissues, drugs that can limit local turnover are available for bone. Suppression of bone turnover should interfere with the growth support for the tumor. Consequently, bone resorption inhibitors are becoming an attractive strategy for preventive and adjuvant therapies in patients with bone lesions.

7.1.1.1 Bisphosphonates

Bisphosphonates (BPs) are non-hydrolysable pyrophosphate analogues, and effective pharmacological bone resorption inhibitors that bind preferentially to bone at sites of active bone metabolism. They are released from the bone matrix during bone resorption and taken up by osteoclasts. BPs potentially inhibit osteoclast activity and survival, thereby reducing osteoclast-mediated bone resorption³⁹²⁻³⁹⁴. In clinical practice, BPs have been widely used to control skeletal complications in various neoplastic diseases. The bisphosphonates zoledronic acid, ibandronate, clodronate and pamidronate are currently given to breast and prostate cancer patients with already established bone metastases to efficiently reduce the number of skeletal-related events (SREs)^{392,395-398}. In addition, BPs may delay the progression and prevent the development of new bone metastatic foci in patients either established or without bone metastasis at the beginning of the treatment^{399,400}. However, a similar study failed to demonstrate a reduction in the number of metastases⁴⁰¹. Subsequently, three clinical trials primarily focused their investigation on the possibility that BP may prevent the development of metastases in women affected by primary breast cancer, but free of bone metastases at the moment of diagnosis. In two of these studies the preventive administration of BP significantly reduced the number of patients developing bone metastases and the number of bone metastases per patient^{397,402}. In one study there was also a significant reduction of the number of visceral metastases⁴⁰². However, in the third study BP treatment did not prevent the development of bone metastases and even seemed to increase the development of non-skeletal metastases⁴⁰³. To resolve the apparent contradiction, two large phase III trials using BPs as adjuvant therapy for primary breast cancer, each enrolling more than 3000 patients with early-stage breast cancer, are underway. The National Surgical Adjuvant Breast Project B-34 trial will determine whether orally administered clodronate (1600 mg daily for 3 years) alone or in combination with chemotherapy

and/or hormonal therapy reduces the incidence of skeletal and non-skeletal metastases or improves overall or relapse-free survival. The Southwest Oncology Group 0307 trial will compare zoledronic acid (4 mg administered intravenously every 4 weeks for 6 months, then every 3 months for 2.5 years), clodronate (1600 mg taken orally daily for 3 years), and the BP ibandronate (50 mg taken orally daily for 3 years) as adjuvant therapy for primary breast cancer. The first results from these clinical trials are expected to be available in 2008. For prostate cancer similar prevention trials are ongoing.

7.1.1.2 Osteoprotegerin

Although the current therapy with BP results in a significant reduction in morbidity, an unmet medical need remains for a more convenient, effective, and safe therapy. Parental BPs must be administered by i.v. infusion. They are not effective in all patients, and renal toxicity and osteonecrosis may limit the dose and use of these agents in certain patients.

OPG is a potent natural bone resorption inhibitor that antagonizes the ability of RANKL to bind its receptor RANK^{139,147,148}. Using the model of intracardiac injection with MDA-231 cells, treatment with Fc-OPG inhibited bone metastases formation from breast cancer³⁷⁴. In addition, in murine models of hypercalcemia, the Fc-OPG was shown to have a greater effect on reduction of bone turnover and osteoclast numbers than BP (pamidronate or zoledronic acid) treatment⁴⁰⁴. Moreover, in a phase I trial a single s.c. dose of OPG (AMGN-0007) suppressed bone resorption in patients with multiple myeloma and bone metastases from breast cancer at least as potently as with i.v. infusion with pamidronate⁴⁰⁵. Furthermore, Denosumab — a fully humanized, neutralizing monoclonal antibody to RANKL — decreased bone turnover markers in patients with multiple myeloma and bone metastases from breast cancer by a similar magnitude but more sustained than with pamidronate (i.v.)⁴⁰⁶. Phase III clinical trials are now focusing their investigation on whether or not denosumab is able to prevent formation of bone metastases from breast cancer and inhibit bone loss induced by hormone ablation therapy in prostate and breast cancer.

7.1.1.3 Cathepsin K Inhibitors

Another class of bone resorption inhibitors that also target osteoclastic bone resorption are cathepsin K inhibitors. In a recent preclinical study, it was shown that a cathepsin K inhibitor reduced breast cancer-induced osteolysis and skeletal tumor burden⁴⁰⁷.

7.1.1.4 Other Treatments

Atrasentan is a small molecule that blocks the functional binding of ET-1 to ETA receptor⁴⁰⁸. ET-1 is a potent mitogen for both prostate cancer cells and osteoblasts, and it is considered to be involved in the generation of pain⁴⁰⁹. Prospective randomized placebo-controlled Phase II and III trials showed that atrasentan (10 mg/day, orally) provided adequate analgesia and a consistent trend demonstrating a delay in disease progression in patients with

metastatic hormone-refractory prostate cancer^{408,410,411}. In theory, ET receptor antagonists seem better suited to act in the early phases of the cancer cell-bone interaction. Therefore, atrasentan is under investigation in a maturing phase 3 study in >900 men with non-metastatic hormone refractory prostate cancer to test the hypothesis that it delays the onset of metastatic disease.

7.2 Future Perspectives

Advances in structural deciphering of biomolecules that are involved in the pathogenesis of bone metastasis — such as OPG, integrins and MMPs — have allowed scientists to design molecules that mimic these critical targets. These artificially designed molecules can be used to block or increase the activity of a particular therapeutic target, and have significant potential in the treatment of bone metastasis. Measurements of bone turnover markers may be beneficial for the planning of a preventive treatment with bone resorption inhibitors, either newly designed molecules or more conventional ones. In the near future, gene signatures from primary cancers that predict bone metastatic potential are also very promising tools to plan adequate treatment⁴¹²⁻⁴¹⁴.

8 Aim and Outline of Thesis

Once a bone metastasis has developed, patients cannot be cured. From then on, their quality of life is often adversely affected by the frequency and morbidity of skeletal-related events (SRE). Therefore, new and better treatments need to be developed, both to inhibit SRE as well as to inhibit the initial formation of bone metastases. To determine the efficacy of such treatments, more sensitive and less invasive methods to directly detect and monitor *in vivo* minimal residual disease (MRD) in preclinical cancer models are required.

In **chapter 2** of this thesis, the possible contribution to metastasis in breast cancer of periodic-acid Schiff (PAS)-positive structures in the primary tumor and its lymph node metastases is studied. In **chapter 3**, whole-body bioluminescent reporter imaging (BLI) is described as a new and better method to detect, monitor and quantify microscopic bone metastases in experimental models. Therefore, optical imaging is used in the following chapters to detect and quantify the effects of different kinds of treatments. In **chapter 4**, clinically relevant doses of bisphosphonate, given in a preventive or treatment protocol, are used to investigate the effects on progression of bone metastases. Subsequently, in **chapter 5**, high-dose bisphosphonate (BP) and osteoprotegerin (OPG) are given to maximally inhibit bone resorption using two different mechanisms of action to study the effects on established bone metastases. In **chapters 6** and **7**, bone morphogenetic protein (BMP7) is tested as a novel therapeutic molecule for repression of local and bone metastatic growth of breast and prostate cancer. Finally, general conclusions and discussions are described in **chapter 8**.

9 References

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. *CA Cancer J Clin* 2007; 57:43-66.
2. Paget S. The distribution of secondary growths in cancer of the breast. *Lancet* 1889; 1:571-3.
3. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. *Br J Cancer* 1987; 55:61-6.
4. Coleman RE. Skeletal complications of malignancy. *Cancer* 1997; 80:1588-94.
5. Galasko C. Incidence and distribution of skeletal metastases. In: *Skeletal Metastasis*, pp. 14-21. London, Butterworths, 1986.
6. Rubens RD. The nature of metastatic bone disease. In: RD Rubens and Fogelman I. (eds.), *Bone metastases – diagnosis and treatment*, pp. 1-10. London, Springer-Verlag, 1991.
7. Walther HE. *Krebsmetastase*. Basel, Beno Schwabe & Co, 1948.
8. Chisholm GD, Rana A, Howard GC. Management options for painful carcinoma of the prostate. *Semin Oncol* 1993; 20:34-7.
9. Berg A, Berner A, Lilleby W, Bruland OS, Fossa SD, Nesland JM *et al*. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. *Int J Cancer* 2007; 120:1603-9.
10. Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F *et al*. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. *J Clin Oncol* 2000; 18:80-6.
11. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC *et al*. A pooled analysis of bone marrow micrometastasis in breast cancer. *N Engl J Med* 2005; 353:793-802.
12. Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF *et al*. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. *J Natl Cancer Inst* 1996; 88:1652-8.
13. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G *et al*. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. *Clin Cancer Res* 2006; 12:5615-21.
14. Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S *et al*. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. *Cancer* 2005; 103:884-91.
15. Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C *et al*. Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. *Clin Cancer Res* 2003; 9:2598-604.
16. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. *Br J Cancer* 1998; 77:336-40.
17. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. *Cancer Treat Rev* 2001; 27:165-76.
18. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. *Nat Rev Cancer* 2002; 2:584-93.
19. Mercadante S. Malignant bone pain: pathophysiology and treatment. *Pain* 1997; 69:1-18.
20. Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. *Endocr Relat Cancer* 2005; 12:549-83.
21. Guise TA, Mundy GR. Cancer and bone. *Endocr Rev* 1998; 19:18-54.
22. Roodman GD. Mechanisms of bone metastasis. *N Engl J Med* 2004; 350:1655-64.
23. Langley RR, Fidler IJ. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. *Endocr Rev* 2007; 28:297-321.
24. Alberts B, Bray D, Lewis J, Raff M, Roberts K, and Watson JD. *Cancer*. In: *Molecular Biology of the Cell*, 3rd ed, pp. 1255-1291. New York & London, Garland Publishing, Inc., 1994.
25. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. *Physiol Rev* 1996; 76:69-125.
26. Chung LW, Baseman A, Assikis V, Zhou HE. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. *J Urol* 2005; 173:10-20.

27. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. *Nature* 2001; 411:375-9.
28. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y, Nakamura T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. *Cancer Res* 1997; 57:3305-13.
29. Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. *Cancer Res* 2000; 60:1254-60.
30. Hayashi N, Sugimura Y, Kawamura J, Donjacour AA, Cunha GR. Morphological and functional heterogeneity in the rat prostatic gland. *Biol Reprod* 1991; 45:308-21.
31. Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. *Cancer Res* 2007; 67:4244-53.
32. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. *Genes Dev* 1996; 10:2462-77.
33. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. *Proc Natl Acad Sci U S A* 2003; 100:8621-3.
34. Ellenrieder V, Hendlar SF, Boeck W, Seufferlein T, Menke A, Ruhland C *et al.* Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. *Cancer Res* 2001; 61:4222-8.
35. Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. *J Biol Chem* 2003; 278:21113-23.
36. Piek E, Moustakas A, Kurisaki A, Heldin CH, Ten Dijke P. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. *J Cell Sci* 1999; 112:4557-68.
37. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. *Nat Rev Cancer* 2002; 2:442-54.
38. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A. TGF-{beta} and the Smad Signaling Pathway Support Transcriptomic Reprogramming during Epithelial-Mesenchymal Cell Transition. *Mol Biol Cell* 2005; 16:1987-2002.
39. Massague J. TGF-beta signal transduction. *Annu Rev Biochem* 1998; 67:753-91.:753-91.
40. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S *et al.* TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. *Science* 2004; 303:848-51.
41. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea--a paradigm shift. *Cancer Res* 2006; 66:1883-90.
42. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med* 1997; 3:730-7.
43. Dick JE. Acute myeloid leukemia stem cells. *Ann N Y Acad Sci* 2005; 1044:1-5.:1-5.
44. Al Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A* 2003; 100:3983-8.
45. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S *et al.* Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. *Cancer Res* 2007; 67:3153-61.
46. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. *Cancer Res* 2005; 65:10946-51.
47. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. *Nature* 2001; 414:105-11.
48. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R *et al.* Prostate cancer stem/progenitor cells: identification, characterization, and implications. *Mol Carcinog* 2007; 46:1-14.
49. Hill RP. Identifying cancer stem cells in solid tumors: case not proven. *Cancer Res* 2006; 66:1891-5.
50. D'Amore PA, Shan Y.Ng., Darland D.C. Angiogenesis. *science and medicine* 1999; 44-53.

51. Risau W. Mechanisms of angiogenesis. *Nature* 1997; 386:671-4.
52. Kumar R, Fidler IJ. Angiogenic molecules and cancer metastasis. *In Vivo* 1998; 12:27-34.
53. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* 1996; 86:353-64.
54. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* 1995; 1:27-31.
55. Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. *J Pathol* 1997; 181:207-12.
56. Boudreau N, Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. *Breast Cancer Res* 2003; 5:140-6.
57. de Jong JS, van Diest PJ, Baak JP. Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer. *Histopathology* 2000; 36:306-12.
58. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. *J Clin Oncol* 1995; 13:765-82.
59. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. *J Natl Cancer Inst* 1996; 88:1764-9.
60. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. *Am J Pathol* 1993; 143:401-9.
61. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. *Am J Pathol* 1995; 147:9-19.
62. Engels K, Fox SB, Harris AL. Angiogenesis as a biologic and prognostic indicator in human breast carcinoma. *EXS* 1997; 79:113-56.:113-56.
63. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. *FASEB J* 1999; 13:9-22.
64. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. *Clin Ther* 2006; 28:1779-802.
65. van der Pluijm G, Lowik C, Papapoulos S. Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem. *Cancer Treat Rev* 2000; 26:11-27.
66. van der Pluijm G, Sijmons B, Vloedgraven H, Deckers M, Papapoulos S, Lowik C. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. *J Bone Miner Res* 2001; 16:1077-91.
67. Mohammed RA, Green A, El Shikh S, Paish EC, Ellis IO, Martin SG. Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. *Br J Cancer* 2007; 96:1092-100.
68. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R *et al*. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. *Nat Med* 2001; 7:186-91.
69. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P *et al*. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. *Nat Med* 2001; 7:192-8.
70. Auguste P, Lemiere S, Larrieu-Lahargue F, Bikfalvi A. Molecular mechanisms of tumor vascularization. *Crit Rev Oncol Hematol* 2005; 54:53-61.
71. Clarijs R, Otte-Holler I, Ruiter DJ, de Waal RM. Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma. *Invest Ophthalmol Vis Sci* 2002; 43:912-8.
72. Folberg R, Pe'er J, Gruman LM, Woolson RF, Jeng G, Montague PR *et al*. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. *Hum Pathol* 1992; 23:1298-305.
73. Thies A, Mangold U, Moll I, Schumacher U. PAS-positive loops and networks as a prognostic indicator in cutaneous malignant melanoma. *J Pathol* 2001; 195:537-42.
74. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Pe'er J *et al*. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. *Ophthalmology* 1993; 100:1389-98.

75. Warso MA, Maniotis AJ, Chen X, Majumdar D, Patel MK, Shilkaitis A *et al.* Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. *Clin Cancer Res* 2001; 7:473-7.
76. Foss AJ, Alexander RA, Hungerford JL, Harris AL, Cree IA, Lightman S. Reassessment of the PAS patterns in uveal melanoma. *Br J Ophthalmol* 1997; 81:240-6.
77. McLean IW, Keefe KS, Burnier MN. Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. *Ophthalmology* 1997; 104:777-80.
78. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J *et al.* Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. *Am J Pathol* 1999; 155:739-52.
79. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. *Am J Pathol* 2000; 156:361-81.
80. Zhang S, Zhang D, Sun B. Vasculogenic mimicry: Current status and future prospects. *Cancer Lett* 2007; 254:157-64.
81. Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM, Jr., Cohen MB *et al.* Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: Role in vasculogenic mimicry. *Prostate* 2002; 50:189-201.
82. Shirakawa K, Kobayashi H, Heike Y, Kawamoto S, Brechbiel MW, Kasumi F *et al.* Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. *Cancer Res* 2002; 62:560-6.
83. McDonald DM, Munn L, Jain RK. Vasculogenic mimicry: how convincing, how novel, and how significant? *Am J Pathol* 2000; 156:383-8.
84. McDonald DM, Foss AJ. Endothelial cells of tumor vessels: abnormal but not absent. *Cancer Metastasis Rev* 2000; 19:109-20.
85. Bissell MJ. Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? *Am J Pathol* 1999; 155:675-9.
86. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. *Curr Opin Cell Biol* 2005; 17:548-58.
87. Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. *Curr Opin Cell Biol* 2004; 16:14-23.
88. Egeblad M, Werb Z. new functions for the matrix metalloproteinases in cancer progression. *nature reviews* 2002; 2:161-74.
89. Nielsen BS, Rank F, Lopez JM, Balbin M, Vizoso F, Lund LR *et al.* Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. *Cancer Res* 2001; 61:7091-100.
90. Hay ED. An overview of epithelio-mesenchymal transformation. *Acta Anat (Basel)* 1995; 154:8-20.
91. Stoker M, Perryman M. An epithelial scatter factor released by embryo fibroblasts. *J Cell Sci* 1985; 77:209-23.
92. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. *Curr Opin Cell Biol* 2003; 15:740-6.
93. Vincent-Salomon A, Thiery JP. Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. *Breast Cancer Res* 2003; 5:101-6.
94. Barasch J, Yang J, Ware CB, Taga T, Yoshida K, Erdjument-Bromage H *et al.* Mesenchymal to epithelial conversion in rat metanephros is induced by LIF. *Cell* 1999; 99:377-86.
95. Dudley AT, Lyons KM, Robertson EJ. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. *Genes Dev* 1995; 9:2795-807.
96. Luo G, Hofmann C, Bronckers AL, Sohocki M, Bradley A, Karsenty G. BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. *Genes Dev* 1995; 9:2808-20.
97. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. *Nat Rev Mol Cell Biol* 2006; 7:131-42.
98. Vukicevic S, Kopp JB, Luyten FP, Sampath TK. Induction of nephrogenic mesenchyme by osteogenic protein 1 [bone morphogenetic protein 7]. *Proc Natl Acad Sci U S A* 1996; 93:9021-6.

99. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. *Nat Rev Mol Cell Biol* 2003; 4:657-65.
100. Dandachi N, Hauser-Kronberger C, More E, Wiesener B, Hacker GW, Dietze O *et al.* Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. *J Pathol* 2001; 193:181-9.
101. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. *Am J Clin Pathol* 1996; 105:394-402.
102. Lombaerts M, van Wezel T, Philippo K, Dierssen JW, Zimmerman RM, Oosting J *et al.* E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. *Br J Cancer* 2006; 94:661-71.
103. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A *et al.* E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. *J Cell Biol* 1991; 113:173-85.
104. Vlemminckx K, Vakaet L, Jr., Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. *Cell* 1991; 66:107-19.
105. Weinberg RA. *The Biology of Cancer*. New York, Garland Science, Taylor&Francis Group, 2004.
106. Bukholm IK, Nesland JM, Borresen-Dale AL. Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [see comments]. *J Pathol* 2000; 190:15-9.
107. Bryden AA, Freemont AJ, Clarke NW, George NJ. Paradoxical expression of E-cadherin in prostatic bone metastases. *BJU Int* 1999; 84:1032-4.
108. Barker N, Clevers H. Tumor environment: a potent driving force in colorectal cancer? *Trends Mol Med* 2001; 7:535-7.
109. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells – an integrated concept of malignant tumour progression. *Nat Rev Cancer* 2005; 5:744-9.
110. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J *et al.* Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. *J Cell Biol* 2002; 156:299-313.
111. Oft M, Heider KH, Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. *Curr Biol* 1998; 19:8:1243-52.
112. Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G *et al.* The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. *Cancer Res* 2006; 66:2202-9.
113. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H *et al.* Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. *J Clin Invest* 2005; 115:339-47.
114. Muller T, Bain G, Wang X, Papkoff J. Regulation of epithelial cell migration and tumor formation by beta-catenin signaling. *Exp Cell Res* 2002; 280:119-33.
115. Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, Larue L. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. *Oncogene* 2001; 20:4942-50.
116. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA *et al.* Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. *Proc Natl Acad Sci U S A* 2001; 98:10356-61.
117. Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira MC, Sobrinho-Simoes M. E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. *Histopathology* 2003; 42:580-7.
118. Butler TP, Gullino PM. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. *Cancer Res* 1975; 35:512-6.
119. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J *et al.* Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. *J Clin Invest* 2004; 114:1714-25.
120. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. *Proc Natl Acad Sci U S A* 2006; 103:9643-8.

121. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. *Cancer Res* 1999; 59:1295-300.
122. Karparkin S, Pearlstein E, Salk PL, Yogeewaran G. Role of platelets in tumor cell metastases. *Ann N Y Acad Sci* 1981; 370:101-18.:101-18.
123. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E *et al.* Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. *Cancer Res* 2002; 62:2824-33.
124. Batson OV. The function of the vertebral veins and their role in the spread of metastasis. *Ann Surg* 1940; 112:138-49.
125. Ibukuro K, Fukuda H, Mori K, Inoue Y. Topographic anatomy of the vertebral venous system in the thoracic inlet. *AJR Am J Roentgenol* 2001; 176:1059-65.
126. Coman DR, deLong RP. The role of the vertebral venous system in the metastasis of cancer to the spinal column; experiments with tumor-cell suspensions in rats and rabbits. *Cancer* 1951; 4:610-8.
127. Baron R Anatomy and Ultrastructure of Bone. In: MJ Favus (ed.), *Primer on the Metabolic Bone Diseases an Disorders of Mineral Metabolism*, 4 ed, pp. 3-10. Philadelphia, Lippincott Williams&Wilkins, 1999.
128. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature* 2003; 423:337-42.
129. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? *Am J Pathol* 2007; 170:427-35.
130. Engleman VW, Nickols GA, Ross FP, Horton MA, Griggs DW, Settle SL *et al.* A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. *J Clin Invest* 1997; 99:2284-92.
131. Marks SCJr, Lane PW. Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse. *J Hered* 1976; 67:11-8.
132. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H *et al.* The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. *Nature* 1990; 345:442-4.
133. Felix R, Cecchini MG, Hofstetter W, Elford PR, Stutzer A, Fleisch H. Impairment of macrophage colony-stimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse. *J Bone Miner Res* 1990; 5:781-9.
134. Felix R, Cecchini MG, Fleisch H. Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. *Endocrinology* 1990; 127:2592-4.
135. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E *et al.* Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. *Proc Natl Acad Sci U S A* 1999; 96:3540-5.
136. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T *et al.* Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell* 1998; 93:165-76.
137. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K *et al.* RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. *Biochem Biophys Res Commun* 1998; 253:395-400.
138. Tsukii K, Shima N, Mochizuki S, Yamaguchi K, Kinosaki M, Yano K *et al.* Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. *Biochem Biophys Res Commun* 1998; 19;246:337-41.
139. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S *et al.* Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci U S A* 1998; 95:3597-602.
140. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T *et al.* RANK is essential for osteoclast and lymph node development. *Genes Dev* 1999; 13:2412-24.
141. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C *et al.* OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. *Nature* 1999; 397:315-23.
142. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL *et al.* RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. *Proc Natl Acad Sci U S A* 2000; 97:1566-71.

143. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA *et al.* c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. *Science* 1994; 266:443-8.
144. Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV *et al.* Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. *J Clin Invest* 2004; 114:475-84.
145. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H *et al.* Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. *J Exp Med* 2005; 202:1261-9.
146. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. *Cytokine Growth Factor Rev* 2004; 15:457-75.
147. Khosla S. Minireview: the OPG/RANKL/RANK system. *Endocrinology* 2001; 142:5050-5.
148. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R *et al.* Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* 1997; 89:309-19.
149. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N *et al.* Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. *Endocrinology* 1998; 139:1329-37.
150. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. *Endocr Rev* 1999; 20:345-57.
151. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C *et al.* osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. *Genes Dev* 1998; 12:1260-8.
152. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T *et al.* Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. *Biochem Biophys Res Commun* 1998; 247:610-5.
153. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S *et al.* Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. *J Exp Med* 2000; 192:463-74.
154. Lian JB, Gary S, Stein GS, Cancelas JA, Robey PG, and Boskey AL Bone Formation: Osteoblasts Lineage Cells, Growth Factors, Matrix Proteins, and the Mineralization Process. In: MJ Favus (ed.), *Primer on the Metabolic Bone Diseases an Disorders of Mineral Metabolism*, 4 ed, pp. 14-29. Philadelphia, Lippincott Williams&Wilkins, 1999.
155. Aubin JE. Bone stem cells. *J Cell Biochem Suppl* 1998; 30-31:73-82.:73-82.
156. Lian JB, Stein GS. Runx2/Cbfa1: a multifunctional regulator of bone formation. *Curr Pharm Des* 2003; 9:2677-85.
157. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. *Cell* 1997; 89:747-54.
158. Ducy P. Cbfa1: a molecular switch in osteoblast biology. *Dev Dyn* 2000; 219:461-71.
159. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR *et al.* Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. *Cell* 1997; 89:765-71.
160. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K *et al.* Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell* 1997; 89:755-64.
161. Korchynskyi O, van Bezooijen RL, Löwik CWGM, and Ten Dijke P Bone morphogenetic protein receptors and nuclear effectors in bone formation. In: S Vukicevic and KT Sampath (eds.), *Bone Morphogenetic Proteins: Regeneration of Bone and Beyond*, pp. 9-44. Basel, Birkhäuser, 2004.
162. van der Horst G, van Bezooijen RL, Deckers MM, Hoogendam J, Visser A, Lowik CW *et al.* Differentiation of murine preosteoblastic KS483 cells depends on autocrine bone morphogenetic protein signaling during all phases of osteoblast formation. *Bone* 2002; 31:661-9.
163. van der Horst G., Farih-Sips H, Lowik CW, Karperien M. Hedgehog stimulates only osteoblastic differentiation of undifferentiated KS483 cells. *Bone* 2003; 33:899-910.

164. Kato M, Patel MS, Lévasséur R, Lobov I, Chang BH, Glass DA *et al.* Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. *J Cell Biol* 2002; 157:303-14.
165. Knothe Tate ML, Adamson JR, Tami AE, Bauer TW. The osteocyte. *Int J Biochem Cell Biol* 2004; 36:1-8.
166. Robey PG, Fedarko NS, Hefferan TE, Bianco P, Vetter UK, Grzesik W *et al.* Structure and molecular regulation of bone matrix proteins. *J Bone Miner Res* 1993; 8 Suppl 2:S483-7.:S483-S487.
167. van der Pluijm G, Vloedgraven HJ, Ivanov B, Robey FA, Grzesik WJ, Robey PG *et al.* Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. *Cancer Res* 1996; 56:1948-55.
168. van der Pluijm G, Vloedgraven H, Papapoulos S, Lowik C, Grzesik W, Kerr J *et al.* Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. *Lab Invest* 1997; 77:665-75.
169. Hauschka PV, Mavrakos AE, Iafrafi MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. *J Biol Chem* 1986; 261:12665-74.
170. Pietrzak WS, Woodell-May J, McDonald N. Assay of bone morphogenetic protein-2, -4, and -7 in human demineralized bone matrix. *J Craniofac Surg* 2006; 17:84-90.
171. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. *Biochem Biophys Res Commun* 2005; 328:679-87.
172. Frost HM. *Bone biodynamics*. Boston, Little Brown, 1964.
173. Mundy GR Bone remodeling. In: MJ Favus (ed.), *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, 4 ed, pp. 30-38. Philadelphia, Lippincott Williams&Wilkins, 1999.
174. Seeman E, Delmas PD. Bone quality--the material and structural basis of bone strength and fragility. *N Engl J Med* 2006; 354:2250-61.
175. Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. *J Biol Chem* 2002; 277:21352-60.
176. Rizo A, Vellenga E, de Haan G, Schuringa JJ. Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? *Hum Mol Genet* 2006; 15 Spec No 2:R210-9.:R210-R219.
177. Taichman RS. Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. *Blood* 2005; 105:2631-9.
178. Yin T, Li L. The stem cell niches in bone. *J Clin Invest* 2006; 116:1195-201.
179. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC *et al.* Osteoblastic cells regulate the hematopoietic stem cell niche. *Nature* 2003; 425:841-6.
180. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG *et al.* Identification of the hematopoietic stem cell niche and control of the niche size. *Nature* 2003; 425:836-41.
181. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T *et al.* Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. *Science* 1999; 283:845-8.
182. Cancelas JA, Lee AW, Prabhakar R, Stringer KF, Zheng Y, Williams DA. Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. *Nat Med* 2005; 11:886-91.
183. Mohle R, Bautz F, Denzlinger C, Kanz L. Transendothelial migration of hematopoietic progenitor cells. Role of chemotactic factors. *Ann NY Acad Sci* 2001; 938:26-34; discussion 34-5.:26-34.
184. Katayama Y, Hidalgo A, Furie BC, Vestweber D, Furie B, Frenette PS. PSGL-1 participates in E-selectin-mediated progenitor homing to bone marrow: evidence for cooperation between E-selectin ligands and alpha4 integrin. *Blood* 2003; 102:2060-7.
185. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L *et al.* G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. *Nat Immunol* 2002; 3:687-94.

186. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark-Lewis I *et al.* Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. *J Biol Chem* 2001; 276:43503-8.
187. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA *et al.* Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. *Cell* 2006; 124:407-21.
188. Semerad CL, Christopher MJ, Liu F, Short B, Simmons PJ, Winkler I *et al.* G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. *Blood* 2005; 106:3020-7.
189. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. *N Engl J Med* 2000; 342:1350-8.
190. Ducy P, Karsenty G. The family of bone morphogenetic proteins. *Kidney Int* 2000; 57:2207-14.
191. Itoh S, Itoh F, Goumans MJ, Ten Dijke P. Signaling of transforming growth factor-beta family members through Smad proteins. *Eur J Biochem* 2000; 267:6954-67.
192. Simic P, Vukicevic S. Bone morphogenetic proteins in development and homeostasis of kidney. *Cytokine Growth Factor Rev* 2005; 16:299-308.
193. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. *Cytokine Growth Factor Rev* 2005; 16:251-63.
194. Massague J. The transforming growth factor-beta family. *Annu Rev Cell Biol* 1990; 6:597-641.:597-641.
195. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. *J Biol Chem* 1983; 258:7155-60.
196. Seyedin SM, Thompson AY, Bentz H, Rosen DM, McPherson JM, Conti A *et al.* Cartilage-inducing factor-A. Apparent identity to transforming growth factor-beta. *J Biol Chem* 1986; 261:5693-5.
197. Seyedin SM, Thomas TC, Thompson AY, Rosen DM, Piez KA. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. *Proc Natl Acad Sci U S A* 1985; 82:2267-71.
198. Janssens K, Ten Dijke P, Janssens S, Van Hul W. Transforming growth factor-beta1 to the bone. *Endocr Rev* 2005; 26:743-74.
199. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. *Nature* 2003; 425:577-84.
200. Massague J. How cells read TGF-beta signals. *Nat Rev Mol Cell Biol* 2000; 1:169-78.
201. Ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Estevez M, Riddle DL *et al.* Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. *J Biol Chem* 1994; 269:16985-8.
202. Liu F, Ventura F, Doody J, Massague J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. *Mol Cell Biol* 1995; 15:3479-86.
203. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. *Growth Factors* 2004; 22:233-41.
204. Miyazono K, Kusanagi K, Inoue H. Divergence and convergence of TGF-beta/BMP signaling. *J Cell Physiol* 2001; 187:265-76.
205. Ebisawa T, Tada K, Kitajima I, Tojo K, Sampath TK, Kawabata M *et al.* Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. *J Cell Sci* 1999; 112:3519-27.
206. Aoki H, Fujii M, Imamura T, Yagi K, Takehara K, Kato M *et al.* Synergistic effects of different bone morphogenetic protein type I receptors on alkaline phosphatase induction. *J Cell Sci* 2001; 114:1483-9.
207. Kim IY, Lee DH, Ahn HJ, Tokunaga H, Song W, Devereaux LM *et al.* Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues. *Cancer Res* 2000; 60:2840-4.
208. Kim IY, Lee DH, Lee DK, Ahn HJ, Kim MM, Kim SJ *et al.* Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. *Oncogene* 2004; 23:7651-9.

209. Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. *Cell* 1991; 67:785-95.
210. Gougos A, Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. *J Biol Chem* 1990; 265:8361-4.
211. Letamendia A, Lastres P, Botella LM, Raab U, Langa C, Velasco B *et al.* Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. *J Biol Chem* 1998; 273:33011-9.
212. Scherner O, Meurer SK, Tihaa L, Gressner AM, Weiskirchen R. Endoglin differentially modulates antagonistic transforming growth factor-beta1 and BMP-7 signaling. *J Biol Chem* 2007; 282:13934-43.
213. Lopez-Casillas F, Wrana JL, Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. *Cell* 1993; 73:1435-44.
214. Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM *et al.* Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. *Nature* 2000; 404:411-4.
215. Yagi K, Goto D, Hamamoto T, Takenoshita S, Kato M, Miyazono K. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. *J Biol Chem* 1999; 274:703-9.
216. Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M *et al.* Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. *J Biol Chem* 2001; 276:19945-53.
217. Phanish MK, Wahab NA, Colville-Nash P, Hendry BM, Dockrell ME. The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. *Biochem J* 2006; 393:601-7.
218. Chaudhry SS, Cain SA, Morgan A, Dallas SL, Shuttleworth CA, Kielty CM. Fibrillin-1 regulates the bioavailability of TGFbeta1. *J Cell Biol* 2007; 176:355-67.
219. Constam DB, Robertson EJ. Regulation of bone morphogenetic protein activity by pro domains and proprotein convertases. *J Cell Biol* 1999; 144:139-49.
220. Gregory KE, Ono RN, Charbonneau NL, Kuo CL, Keene DR, Bachinger HP *et al.* The prodomain of BMP-7 targets the BMP-7 complex to the extracellular matrix. *J Biol Chem* 2005;..
221. Sampath TK, Maliakal JC, Hauschka PV, Jones WK, Sasak H, Tucker RF *et al.* Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. *J Biol Chem* 1992; 267:20352-62.
222. Ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. *Nat Rev Mol Cell Biol* 2007; 8:857-69.
223. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. *J Cell Sci* 2003; 116:217-24.
224. Kanzaki T, Olofsson A, Moren A, Wernstedt C, Hellman U, Miyazono K *et al.* TGF-beta 1 binding protein: a component of the large latent complex of TGF-beta 1 with multiple repeat sequences. *Cell* 1990; 61:1051-61.
225. Saharinen J, Taipale J, Keski-Oja J. Association of the small latent transforming growth factor-beta with an eight cysteine repeat of its binding protein LTBP-1. *EMBO J* 1996; 15:245-53.
226. Dallas SL, Park-Snyder S, Miyazono K, Twardzik D, Mundy GR, Bonewald LF. Characterization and autoregulation of latent transforming growth factor beta (TGF beta) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF beta-binding protein. *J Biol Chem* 1994; 269:6815-21.
227. Saharinen J, Keski-Oja J. Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. *Mol Biol Cell* 2000; 11:2691-704.
228. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R *et al.* Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. *J Biol Chem* 2003; 278:2750-7.

229. Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W *et al.* Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. *Nature* 2002; 420:636-42.
230. Ross JJ, Shimmi O, Vilmos P, Petryk A, Kim H, Gaudenz K *et al.* Twisted gastrulation is a conserved extracellular BMP antagonist. *Nature* 2001; 410:479-83.
231. Bachiller D, Klingensmith J, Kemp C, Belo JA, Anderson RM, May SR *et al.* The organizer factors Chordin and Noggin are required for mouse forebrain development. *Nature* 2000; 403:658-61.
232. Pearce JJ, Penny G, Rossant J. A mouse cerberus/Dan-related gene family. *Dev Biol* 1999; 209:98-110.
233. Gazzerro E, Canalís E. Bone morphogenetic proteins and their antagonists. *Rev Endocr Metab Disord* 2006; 7:51-65.
234. Massague J, Seoane J, Wotton D. Smad transcription factors. *Genes Dev* 2005; 19:2783-810.
235. Afrakhte M, Moren A, Jossan S, Itoh S, Sampath K, Westermarck B *et al.* Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. *Biochem Biophys Res Commun* 1998; 249:505-11.
236. Ishisaki A, Yamato K, Hashimoto S, Nakao A, Tamaki K, Nonaka K *et al.* Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. *J Biol Chem* 1999; 274:13637-42.
237. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R *et al.* Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. *Nature* 1997; 389:631-5.
238. Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback regulation of TGF-beta signalling by the SnoN oncoprotein. *Science* 1999; 286:771-4.
239. Takase M, Imamura T, Sampath TK, Takeda K, Ichijo H, Miyazono K *et al.* Induction of Smad6 mRNA by bone morphogenetic proteins. *Biochem Biophys Res Commun* 1998; 244:26-9.
240. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massague J *et al.* Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. *Nature* 1999; 401:480-5.
241. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M *et al.* Smad6 inhibits signalling by the TGF-beta superfamily. *Nature* 1997; 389:622-6.
242. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW *et al.* The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. *Cell* 1997; 89:1165-73.
243. Hata A, Lagna G, Massague J, Hemmati-Brivanlou A. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. *Genes Dev* 1998; 12:186-97.
244. Lin X, Liang M, Feng XH. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. *J Biol Chem* 2000; 275:36818-22.
245. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. *Proc Natl Acad Sci U S A* 2001; 98:974-9.
246. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. *Nature* 1999; 400:687-93.
247. Murakami G, Watabe T, Takaoka K, Miyazono K, Imamura T. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. *Mol Biol Cell* 2003; 14:2809-17.
248. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH *et al.* Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. *Mol Cell* 2000; 6:1365-75.
249. Suzuki C, Murakami G, Fukuchi M, Shimanuki T, Shikauchi Y, Imamura T *et al.* Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. *J Biol Chem* 2002; 277:39919-25.
250. Tajima Y, Goto K, Yoshida M, Shinomiya K, Sekimoto T, Yoneda Y *et al.* Chromosomal region maintenance 1 (CRM1)-dependent nuclear export of Smad ubiquitin regulatory factor 1 (Smurf1) is essential for negative regulation of transforming growth factor-beta signaling by Smad7. *J Biol Chem* 2003; 278:10716-21.

251. Luo K, Stroschein SL, Wang W, Chen D, Martens E, Zhou S *et al.* The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. *Genes Dev* 1999; 13:2196-206.
252. Sun Y, Liu X, Ng-Eaton E, Lodish HF, Weinberg RA. SnoN and Ski protooncoproteins are rapidly degraded in response to transforming growth factor beta signaling. *Proc Natl Acad Sci U S A* 1999; 96:12442-7.
253. Akiyoshi S, Inoue H, Hanai J, Kusanagi K, Nemoto N, Miyazono K *et al.* c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads. *J Biol Chem* 1999; 274:35269-77.
254. Sun Y, Liu X, Eaton EN, Lane WS, Lodish HF, Weinberg RA. Interaction of the Ski oncoprotein with Smad3 regulates TGF-beta signaling. *Mol Cell* 1999; 4:499-509.
255. Takeda M, Mizuide M, Oka M, Watabe T, Inoue H, Suzuki H *et al.* Interaction with Smad4 is indispensable for suppression of BMP signaling by c-Ski. *Mol Biol Cell* 2004; 15:963-72.
256. Wang W, Mariani FV, Harland RM, Luo K. Ski represses bone morphogenic protein signaling in *Xenopus* and mammalian cells. *Proc Natl Acad Sci U S A* 2000; 97:14394-9.
257. Xu W, Angelis K, Danielpour D, Haddad MM, Bischof O, Campisi J *et al.* Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor. *Proc Natl Acad Sci U S A* 2000; 97:5924-9.
258. Yoshida Y, von Bubnoff A, Ikematsu N, Blitz IL, Tsuzuku JK, Yoshida EH *et al.* Tob proteins enhance inhibitory Smad-receptor interactions to repress BMP signaling. *Mech Dev* 2003; 120:629-37.
259. Yoshida Y, Tanaka S, Umemori H, Minowa O, Usui M, Ikematsu N *et al.* Negative regulation of BMP/Smad signaling by Tob in osteoblasts. *Cell* 2000; 103:1085-97.
260. Calonge MJ, Massague J. Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells. *J Biol Chem* 1999; 274:33637-43.
261. Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. *Nature* 1997; 389:618-22.
262. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. *Genes Dev* 1999; 13:804-16.
263. Ten Dijke P, Korchynskiy O, Valdimarsdottir G, Goumans MJ. Controlling cell fate by bone morphogenetic protein receptors. *Mol Cell Endocrinol* 2003; 211:105-13.
264. Reddi AH. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. *Nat Biotechnol* 1998; 16:247-52.
265. Graff JM. Embryonic patterning: to BMP or not to BMP, that is the question. *Cell* 1997; 89:171-4.
266. Barnes J, Anthony CT, Wall N, Steiner MS. Bone morphogenetic protein-6 expression in normal and malignant prostate. *World J Urol* 1995; 13:337-43.
267. Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE, Robson CN. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. *Cancer Res* 1997; 57:4427-31.
268. Clement JH, Raida M, Sanger J, Bicknell R, Liu J, Naumann A *et al.* Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. *Int J Oncol* 2005; 27:401-7.
269. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. *Cancer Res* 2005; 65:8274-85.
270. Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P *et al.* Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. *J Bone Miner Res* 2005; 20:2189-99.
271. Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM *et al.* Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. *Bone* 2006; 38:154-66.
272. Maliakal JC, Asahina I, Hauschka PV, Sampath TK. Osteogenic protein-1 (BMP-7) inhibits cell proliferation and stimulates the expression of markers characteristic of osteoblast phenotype in rat osteosarcoma (17/2.8) cells. *Growth Factors* 1994; 11:227-34.
273. Yeh LC, Adamo ML, Olson MS, Lee JC. Osteogenic protein-1 and insulin-like growth factor I synergistically stimulate rat osteoblastic cell differentiation and proliferation. *Endocrinology* 1997; 138:4181-90.

274. Yang S, Lim M, Pham LK, Kendall SE, Reddi AH, Altieri DC *et al.* Bone morphogenetic protein 7 protects prostate cancer cells from stress-induced apoptosis via both Smad and c-Jun NH2-terminal kinase pathways. *Cancer Res* 2006; 66:4285-90.
275. Seoane J. Escaping from the TGFbeta anti-proliferative control. *Carcinogenesis* 2006; 27:2148-56.
276. Gorska AE, Jensen RA, Shyr Y, Aakre ME, Bhowmick NA, Moses HL. Transgenic Mice Expressing a Dominant-Negative Mutant Type II Transforming Growth Factor-beta Receptor Exhibit Impaired Mammary Development and Enhanced Mammary Tumor Formation. *Am J Pathol* 2003; 163:1539-49.
277. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J *et al.* Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. *J Clin Invest* 2002; 109:1551-9.
278. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J *et al.* Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. *J Clin Invest* 2002; 109:1607-15.
279. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. *Nat Rev Drug Discov* 2004; 3:1011-22.
280. Ma L, Lu MF, Schwartz RJ, Martin JF. Bmp2 is essential for cardiac cushion epithelial-mesenchymal transition and myocardial patterning. *Development* 2005; 132:5601-11.
281. Theriault BL, Shepherd TG, Mujoomdar ML, Nachtigal MW. BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. *Carcinogenesis* 2007; 28:1153-62.
282. Zeisberg M, Shah AA, Kalluri R. Bone morphogenetic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. *J Biol Chem* 2005; 280:8094-100.
283. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. *J Clin Invest* 2003; 112:1776-84.
284. Hruska KA, Guo G, Wozniak M, Martin D, Miller S, Liapis H *et al.* Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. *Am J Physiol Renal Physiol* 2000; 279:F130-F143.
285. Wang S, Hirschberg R. BMP7 antagonizes TGF-beta -dependent fibrogenesis in mesangial cells. *Am J Physiol Renal Physiol* 2003; 284:F1006-F1013.
286. Gould SE, Day M, Jones SS, Dorai H. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. *Kidney Int* 2002; 61:51-60.
287. Vukicevic S, Basic V, Rogic D, Basic N, Shih MS, Shepard A *et al.* Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. *J Clin Invest* 1998; 102:202-14.
288. Wang S, Chen Q, Simon TC, Strebeck F, Chaudhary L, Morrissey J *et al.* Bone morphogenetic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. *Kidney Int* 2003; 63:2037-49.
289. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F *et al.* BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. *Nat Med* 2003; 9:964-8.
290. Gonzalez EA, Lund RJ, Martin KJ, McCartney JE, Tondravi MM, Sampath TK *et al.* Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. *Kidney Int* 2002; 61:1322-31.
291. Lund RJ, Davies MR, Brown AJ, Hruska KA. Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. *J Am Soc Nephrol* 2004; 15:359-69.
292. Davies MR, Lund RJ, Hruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. *J Am Soc Nephrol* 2003; 14:1559-67.
293. Giannoudis PV, Tzioupis C. Clinical applications of BMP-7: the UK perspective. *Injury* 2005; 36 Suppl 3:S47-S50.
294. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. *Cell* 1994; 76:301-14.
295. Garlanda C, Dejana E. Heterogeneity of endothelial cells. Specific markers. *Arterioscler Thromb Vasc Biol* 1997; 17:1193-202.

296. Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W *et al.* Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. *Cancer Res* 2005; 65:5750-60.
297. Dimitroff CJ, Lechpammer M, Long-Woodward D, Kutok JL. Rolling of human bone-metastatic prostate tumor cells on human bone marrow endothelium under shear flow is mediated by E-selectin. *Cancer Res* 2004; 64:5261-9.
298. Sipkins DA, Wei X, Wu JW, Runnels JM, Cote D, Means TK *et al.* In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. *Nature* 2005; 435:969-73.
299. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME *et al.* Involvement of chemokine receptors in breast cancer metastasis. *Nature* 2001; 410:50-6.
300. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J *et al.* Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. *J Bone Miner Res* 2005; 20:318-29.
301. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. *Cancer Res* 2002; 62:1832-7.
302. Guo W, Giancotti FG. Integrin signalling during tumour progression. *Nat Rev Mol Cell Biol* 2004; 5:816-26.
303. Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ, Taichman RS. Expression and activation of alpha(v)beta(3) integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. *Prostate* 2007; 67:61-73.
304. Harms JF, Welch DR, Samant RS, Shevde LA, Miele ME, Babu GR *et al.* A small molecule antagonist of the alpha(v)beta(3) integrin suppresses MDA-MB-435 skeletal metastasis. *Clin Exp Metastasis* 2004; 21:119-28.
305. Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R *et al.* Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. *Cancer Res* 2007; 67:5821-30.
306. McCabe NP, De S, Vasanthi A, Brainard J, Byzova TV. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. *Oncogene* 2007; 26:6238-43.
307. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Volland C, Bourre F *et al.* Integrin alpha(v) beta3 expression confers on tumor cells a greater propensity to metastasize to bone. *FASEB J* 2002; 16:1266-8.
308. Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK *et al.* Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. *Breast Cancer Res* 2006; 8:R20.
309. Karadag A, Ogbureke KU, Fedarko NS, Fisher LW. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. *J Natl Cancer Inst* 2004; 96:956-65.
310. Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. *Proc Natl Acad Sci USA* 2003; 100:9482-7.
311. Hill A, McFarlane S, Johnston PG, Waugh DJ. The emerging role of CD44 in regulating skeletal micrometastasis. *Cancer Lett* 2006; 237:1-9.
312. Kucia M, Reza R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A *et al.* Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. *Stem Cells* 2005; 23:879-94.
313. Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. *Am J Pathol* 1995; 146:95-100.
314. Bellahcene A, Kroll M, Liebens F, Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. *J Bone Miner Res* 1996; 11:665-70.
315. Knerr K, Ackermann K, Neidhart T, Pyerin W. Bone metastasis: Osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry. *Int J Cancer* 2004; 111:152-9.

316. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. *Prostate* 1999; 39:246-61.
317. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C *et al.* VEGFR1-positive hematopoietic bone marrow progenitors initiate the pre-metastatic niche. *Nature* 2005; 438:820-7.
318. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. *Cancer Res* 2006; 66:11089-93.
319. Arguello F, Baggs RB, Graves BT, Harwell SE, Cohen HJ, Frantz CN. Effect of IL-1 on experimental bone/bone-marrow metastases. *Int J Cancer* 1992; 52:802-7.
320. Kostenuik PJ, Singh G, Suyama KL, Orr FW. Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone. *Clin Exp Metastasis* 1992; 10:411-8.
321. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ *et al.* Bone turnover mediates preferential localization of prostate cancer in the skeleton. *Endocrinology* 2005; 146:1727-36.
322. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. *Br J Cancer* 2003; 89:2031-7.
323. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M *et al.* Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. *J Natl Cancer Inst* 2005; 97:59-69.
324. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M *et al.* Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. *J Clin Oncol* 2005; 23:4925-35.
325. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC *et al.* Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. *J Clin Oncol* 2002; 20:850-6.
326. Garnero P. Markers of bone turnover in prostate cancer. *Cancer Treat Rev* 2001; 27:187-92.
327. Blair JM, Zhou H, Seibel MJ, Dunstan CR. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. *Nat Clin Pract Oncol* 2006; 3:41-9.
328. Clohisy DR, Ramnaraine ML. Osteoclasts are required for bone tumors to grow and destroy bone. *J Orthop Res* 1998; 16:660-6.
329. Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. *Cancer* 2003; 97:834-9.
330. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ *et al.* Breast cancer cells interact with osteoblasts to support osteoclast formation. *Endocrinology* 1999; 140:4451-8.
331. Southby J, Kissin MW, Danks JA, Hayman JA, Moseley JM, Henderson MA *et al.* Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. *Cancer Res* 1990; 50:7710-6.
332. Iddon J, Bundred NJ, Hoyland J, Downey SE, Baird P, Salter D *et al.* Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer. *J Pathol* 2000; 191:170-4.
333. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF *et al.* Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. *J Clin Invest* 1996; 98:1544-9.
334. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA *et al.* Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. *Cancer Res* 1991; 51:3059-61.
335. Kissin MW, Henderson MA, Danks JA, Hayman JA, Bennett RC, Martin TJ. Parathyroid hormone related protein in breast cancers of widely varying prognosis. *Eur J Surg Oncol* 1993; 19:134-42.
336. Bundred NJ, Walker RA, Ratcliffe WA, Warwick J, Morrison JM, Ratcliffe JG. Parathyroid hormone related protein and skeletal morbidity in breast cancer. *Eur J Cancer* 1992; 28:690-2.
337. Henderson M, Danks J, Moseley J, Slavin J, Harris T, McKinlay M *et al.* Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. *J Natl Cancer Inst* 2001; 93:234-7.

338. Henderson MA, Danks JA, Slavin JL, Byrnes GB, Choong PF, Spillane JB *et al.* Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. *Cancer Res* 2006; 66:2250-6.
339. Kohno N, Kitazawa S, Sakoda Y, Kanbara Y, Furuya Y, Ohashi O *et al.* Parathyroid Hormone-related Protein in Breast Cancer Tissues: Relationship between Primary and Metastatic Sites. *Breast Cancer* 1994; 1:43-9.
340. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R *et al.* TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. *J Clin Invest* 1999; 103:197-206.
341. Virk MS, Lieberman JR. Tumor metastasis to bone. *Arthritis Res Ther* 2007; 9 Suppl 1:S5.:S5.
342. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. *Bone* 2003; 33:28-37.
343. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T *et al.* NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. *Nat Med* 2007; 13:62-9.
344. Cecchini MG, Wetterwald A, van der Pluijm G, Thalmann GN. Molecular and Biological Mechanisms of Bone Metastasis. *EAU Update Series* 2005; 3:214-26.
345. Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T, Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. *J Urol* 1997; 157:539-43.
346. Ye L, Lewis-Russell JM, Kyanaston HG, Jiang WG. Bone morphogenetic proteins and their receptor signaling in prostate cancer. *Histol Histopathol* 2007; 22:1129-47.
347. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S *et al.* Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. *Cancer Res* 2004; 64:994-9.
348. Schwaninger R, Rentsch CA, Wetterwald A, van der Horst G, van Bezooijen RL, van der Pluijm G *et al.* Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. *Am J Pathol* 2007; 170:160-75.
349. Hall CL, Kang S, MacDougald OA, Keller ET. Role of Wnts in prostate cancer bone metastases. *J Cell Biochem* 2006; 97:661-72.
350. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B *et al.* The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. *N Engl J Med* 2003; 349:2483-94.
351. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clezardin P *et al.* Increased Dickkopf-1 expression in breast cancer bone metastases. *Br J Cancer* 2007; 97:964-70.
352. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. *Nat Rev Cancer* 2005; 5:21-8.
353. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA *et al.* Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. *Nat Med* 1995; 1:944-9.
354. Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LW *et al.* New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. *Urology* 1999; 53:1063-9.
355. Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D *et al.* In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. *Cancer Res* 2007; 67:3818-26.
356. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL *et al.* A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. *Proc Natl Acad Sci U S A* 2003; 100:10954-9.
357. Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J *et al.* An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. *Biochem Biophys Res Commun* 1990; 173:1058-64.
358. Cohen P, Peehl DM, Graves HC, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. *J Endocrinol* 1994; 142:407-15.
359. Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. *J Urol* 1996; 156:526-31.

360. Singh AS, Figg WD. In vivo models of prostate cancer metastasis to bone. *J Urol* 2005; 174:820-6.
361. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S, Contag CH. Animal models of bone metastasis. *Cancer* 2003; 97:748-57.
362. Waters DJ, Sakr WA, Hayden DW, Lang CM, McKinney L, Murphy GP *et al.* Workgroup 4: spontaneous prostate carcinoma in dogs and nonhuman primates. *Prostate* 1998; 36:64-7.
363. Pollard M. Lobund-Wistar rat model of prostate cancer in man. *Prostate* 1998; 37:1-4.
364. Varma VA, Austin GE. Morphologic characterization of early prostatic carcinomas in the ACI rat: a light and electron microscopic study. *Exp Mol Pathol* 1990; 52:202-11.
365. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr., Butel JS *et al.* Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. *Nature* 1992; 356:215-21.
366. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE *et al.* Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. *Mol Cell Biol* 2003; 23:8691-703.
367. Duan W, Gabril MY, Moussa M, Chan FL, Sakai H, Fong G *et al.* Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model. *Oncogene* 2005; 24:1510-24.
368. Derksen PW, Liu X, Saridin F, van der GH, Zevenhoven J, Evers B *et al.* Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. *Cancer Cell* 2006; 10:437-49.
369. Kostenuik PJ, Singh G, Suyama KL, Orr FW. A quantitative model for spontaneous bone metastasis: evidence for a mitogenic effect of bone on Walker 256 cancer cells. *Clin Exp Metastasis* 1992; 10:403-10.
370. Berlin O, Samid D, Donthineni-Rao R, Akeson W, Amiel D, Woods VL, Jr. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. *Cancer Res* 1993; 53:4890-5.
371. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM *et al.* Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. *Prostate* 2002; 52:20-33.
372. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. *Cancer Res* 1988; 48:6876-81.
373. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ *et al.* Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. *Clin Cancer Res* 1996; 2:1627-36.
374. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. *Cancer Res* 2001; 61:4432-6.
375. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R *et al.* Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. *Cancer Res* 1995; 55:3551-7.
376. Yoneda T. Arterial microvascularization and breast cancer colonization in bone. *Histol Histopathol* 1997; 12:1145-9.
377. Kuperwasser C, Chavarría T, Wu M, Magrane G, Gray JW, Carey L *et al.* Reconstruction of functionally normal and malignant human breast tissues in mice. *Proc Natl Acad Sci U S A* 2004; 101:4966-71.
378. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P *et al.* A novel orthotopic model of breast cancer metastasis to bone. *Clin Exp Metastasis* 1999; 17:163-70.
379. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. *Cancer Res* 1992; 52:1399-405.
380. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. *Invest New Drugs* 1999; 17:343-59.
381. Thalmann GN, Anezinis PE, Chang SM, Zhou HE, Kim EE, Hopwood VL *et al.* Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. *Cancer Res* 1994; 54:2577-81.
382. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M *et al.* LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. *Prostate* 2000; 44:91-103.

383. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF *et al.* Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. *Int J Cancer* 1998; 77:887-94.
384. Nemeth JA, Harb JF, Barroso U, Jr., He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. *Cancer Res* 1999; 59:1987-93.
385. Yonou H, Yokose T, Kamijo T, Kanomata N, Hasebe T, Nagai K *et al.* Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. *Cancer Res* 2001; 61:2177-82.
386. Kuperwasser C, Dessain S, Bierbaum BE, Garnet D, Sperandio K, Gauvin GP *et al.* A mouse model of human breast cancer metastasis to human bone. *Cancer Res* 2005; 65:6130-8.
387. Moreau JE, Anderson K, Mauney JR, Nguyen T, Kaplan DL, Rosenblatt M. Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. *Cancer Res* 2007; 67:10304-8.
388. Henriquez NV, van Overveld PG, Que I, Buijs JT, Bachelier R, Kaijzel EL *et al.* Advances in optical imaging and novel model systems for cancer metastasis research. *Clin Exp Metastasis* 2007; 24:699-705.
389. Kaijzel EL, van der Pluijm G, Lowik CWGM. Whole-body optical imaging in animal models to assess cancer development and progression. *Clin Cancer Res* 2007; 13:3490-7.
390. Janjan NA. Radiation for bone metastases: conventional techniques and the role of systemic radiopharmaceuticals. *Cancer* 1997; 80:1628-45.
391. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM *et al.* A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. *Eur J Cancer* 1991; 27:954-8.
392. Coleman RE. Bisphosphonates in breast cancer. *Ann Oncol* 2005; 16:687-95.
393. Fleisch H. Development of bisphosphonates. *Breast Cancer Res* 2002; 4:30-4.
394. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. *J Clin Oncol* 2005; 23:8219-24.
395. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA *et al.* Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. *Ann Oncol* 2003; 14:1399-405.
396. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K *et al.* Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. *Cancer* 2000; 88:1082-90.
397. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A *et al.* Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. *Breast Cancer Res* 2006; 8:R13.
398. Rosen LS, Gordon DH, Dugan W, Jr., Major P, Eisenberg PD, Provencher L *et al.* Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. *Cancer* 2004; 100:36-43.
399. Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. *Bone* 1996; 19:663-7.
400. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D *et al.* Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. *J Clin Oncol* 1996; 14:2552-9.
401. van Holten-Verzantvoort AT, Hermans J, Beex LV, Blijham G, Cleton FJ, Eck-Smit BC *et al.* Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? *Eur J Cancer* 1996; 32A:450-4.
402. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D *et al.* Reduction in new metastases in breast cancer with adjuvant clodronate treatment. *N Engl J Med* 1998; 339:357-63.

403. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. *Acta Oncol* 2004; 43:650-6.
404. Morony S, Warmington K, Adamu S, Asuncion F, Geng Z, Grisanti M *et al.* The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. *Endocrinology* 2005; 146:3235-43.
405. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Femand JP *et al.* A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. *Cancer* 2003; 97:887-92.
406. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M *et al.* A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. *Clin Cancer Res* 2006; 12:1221-8.
407. Le Gall C, Bellahcene A, Bonnelye E, Gasser JA, Castronovo V, Green J *et al.* A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. *Cancer Res* 2007; 67:9894-902.
408. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. *Clin Cancer Res* 2006; 12:6296s-300s.
409. Yuyama H, Koakutsu A, Fujiyasu N, Tanahashi M, Fujimori A, Sato S *et al.* Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. *Eur J Pharmacol* 2004; 492:177-82.
410. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD *et al.* Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. *J Clin Oncol* 2003; 21:679-89.
411. Cella D, Petrylak DP, Fishman M, Teigland C, Young J, Mulani P. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life? *Eur Urol* 2006; 49:781-9.
412. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C *et al.* A multigenic program mediating breast cancer metastasis to bone. *Cancer Cell* 2003; 3:537-49.
413. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M *et al.* Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. *J Clin Invest* 2005; 115:44-55.
414. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D *et al.* Genes associated with breast cancer metastatic to bone. *J Clin Oncol* 2006; 24:2261-7.
415. Schmiere B, Hill CS. TGF-beta-SMAD signal transduction: molecular specificity and functional flexibility. *Nat Rev Mol Cell Biol* 2007; 8:970-82.
416. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I. *EMBO J* 2002; 21:1743-53.
417. Macias-Silva M, Hoodless PA, Tang SJ, Buchwald M, Wrana JL. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. *J Biol Chem* 1998; 273:25628-36.
418. Tamaki K, Souchelnytskyi S, Itoh S, Nakao A, Sampath K, Heldin CH *et al.* Intracellular signaling of osteogenic protein-1 through Smad5 activation. *J Cell Physiol* 1998; 177:355-63.
419. Yamashita H, ten Dijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC *et al.* Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. *J Cell Biol* 1995; 130:217-26.

